Epigenetic timing effects on child developmental outcomes:
A longitudinal meta-regression of findings from the Pregnancy And Childhood

Epigenetics Consortium
Alexander Neumann¹, Sara Sammallahti^{2,3}, Marta Cosin-Tomas^{4,5,6}, Sarah E Reese⁷, Matthew
Suderman⁸, Silvia Alemany^{9,10,11}, Catarina Almqvist¹², Sandra Andrusaityte¹³, Syed H re Book
1999 - Marta Cosin-Tom
1999 - Catarina Almqvist¹², Sandra
1999 - Tallande Bellin
1999 - Tabalaa^{19,} Calasta I /
/
|}
|} Alexander Neumann⁴, Sara Sammallahti^{2,3}, Marta Cosin-Tomas^{4,3,6}, Sarah E Reese'
Suderman⁸, Silvia Alemany^{9,10,11}, Catarina Almqvist¹², Sandra Andrusaityte¹³, Syed
Arshad¹⁴, Marian J Bakermans-Kranenburg¹⁵ Bustamante^{4,5,6}, Darina Czamara¹⁸, Dana Dabelea¹⁹, Celeste Eng²⁰, Brenda Eskenazi²¹,
Bernard F Fuemmeler²², Frank D Gilliland²³, Regina Grazuleviciene¹³, Siri E Håberg²⁴, Gunda
Herberth²⁵, Nina Holland Suderman", Silvia Alemany^{2, 20},²¹, Catarina Almqvist²², Sandra Andrusaityte²², Syed H
Arshad¹⁴, Marian J Bakermans-Kranenburg¹⁵, Lawrence Beilin¹⁶, Carrie Breton¹⁷, Mar
Bustamante^{4,5,6}, Darina Czamara¹⁸ Arshad⁴⁺, Marian J Bakermans-Kranenburg²⁵, Lawrence Beilin²⁶, Carrie Breton²⁷, Mariona
Bustamante^{4,5,6}, Darina Czamara¹⁸, Dana Dabelea¹⁹, Celeste Eng²⁰, Brenda Eskenazi²¹,
Bernard F Fuemmeler²², Frank D Bustamante^{4,5,6}, Darina Czamara²⁶, Dana Dabelea²⁵, Celeste Eng²⁶, Brenda Eskenazi²⁴, Gernard F Fuemmeler²², Frank D Gilliland²³, Regina Grazuleviciene¹³, Siri E Håberg²⁴, G
Herberth²⁵, Nina Holland²⁶, Bernard F Fuemmeler²², Frank D Gilliland²³, Regina Grazuleviciene²⁵, Siri E Håberg²⁷, Gunda
Herberth²⁵, Nina Holland²⁶, Amy Hough²⁷, Donglei Hu²⁸, Karen Huen²⁶, Anke Hüls^{29,30,31},
Jianping Jin³², Jord Herberth²⁵, Nina Holland²⁶, Amy Hough²⁷, Donglei Hu²⁸, Karen Huen²⁶, Anke Hüls^{29,30,31},
Jianping Jin³², Jordi Julvez³³, Berthold V Koletzko³⁴, Gerard H Koppelman³⁵, Inger Kull³⁶,
Xueling Lu³⁷, Léa M Jianping Jin²², Jordi Julvez³³, Berthold V Koletzko³⁴, Gerard H Koppelman³³, Inger Kull³⁹, Xueling Lu³⁷, Léa Maitre^{38,39}, Dan Mason²⁷, Erik Melén⁴⁰, Simon K Merid⁴⁰, Peter L Mollo
Trevor A Mori¹⁶, Ros Xueling Lu³⁷, Léa Maitre^{38,39}, Dan Mason²⁷, Erik Melén⁴⁰, Simon K Merid⁴⁰, Peter L Molloy¹⁴,
Trevor A Mori¹⁶, Rosa H Mulder⁴², Christian M Page⁴³, Rebecca C Richmond⁸, Stefan Röder⁴⁴
Jason P Ross⁴⁵, Trevor A Mori¹⁶, Rosa H Mulder⁴², Christian M Page⁴³, Rebecca C Richmond°, Stefan Röder⁴⁷, Jason P Ross⁴⁵, Laura Schellhas⁴⁶, Sylvain Sebert⁴⁷, Dean Sheppard⁴⁸, Harold Snieder³⁷, Anne
P Starling⁴⁹, Dan Jason P Ross⁻⁻, Laura Schellhas⁻⁻, Sylvain Sebert⁻⁻, Dean Sheppard⁻⁻, Harold Snieder⁻⁻, Anne
P Starling⁴⁹, Dan J Stein⁵⁰, Gwen Tindula⁵¹, Marinus H van IJzendoorn^{52,53}, Judith Vonk^{54,55},
Esther Walton⁵ P Starling"", Dan J Stein"", Gwen Tindula"", Marinus H van IJzendoorn"","", Judith Vonk"","",
Esther Walton⁵⁶, Jonathan Witonsky⁵⁷, Cheng-Jian Xu^{58,59}, Ivana V Yang⁶⁰, Paul D Yousefi⁸,
Heather J Zar⁶¹, Ana C Ze

Heather J Zar⁶¹, Ana C Zenclussen²⁵, Hongmei Zhang⁶², Henning Tiemeier^{1,63}, Stephanie J
London⁶⁴, Janine F Felix^{65,66}, Charlotte Cecil^{1,67,68}
¹Child and adolescent psychiatry/psychology, Erasmus MC, Univer ,
,
, Heather J Zar^{os}, Ana C Zenclussen²⁵, Hongmei Zhang^{o2}, Henning Tiemeier^{3,83}, Stephanie J
London⁶⁴, Janine F Felix^{65,66}, Charlotte Cecil^{1,67,68}
¹Child and adolescent psychiatry/psychology, Erasmus MC, Univers London^{et}, Janine F Felix^{95,66}, Charlotte Cecil^{4,67,68}
¹Child and adolescent psychiatry/psychology, Era
Rotterdam, Netherlands, ²Department of Obstet
Finland, ³Helsinki University Hospital, Finland, ⁴IS
(UPF), 1
|-
| (\ ¹Child and adolescent psychiatry/psychology, Erasmus MC, University Medical Center Rotterdam, Netherlands, ²Department of Obstetrics and Gynecology, University of Helsinki,
Finland, ³Helsinki University Hospital, Finland, ⁴ISGlobal, Spain, ⁵Universitty of Helsinki,
Finland, ³Helsinki University Medical School, University of Bristol, UK, "Psychiatric Genetics Unit, Group of Psychiatry,
Mental Health and Addictions, Vall d'Hebron Research Institute (VHIR), Spain, ¹⁰Department
of Mental health, Hospital Universita of Mental health, Hospital Universitari Vall d'Hebron, Spain, ¹¹Biomedical Network Research
Centre on Mental Health (CIBERSAM), Biomedical Network Research Centre on Mental
Health (CIBERSAM), Instituto de Salud Carlos II Health (CIBERSAM), Instituto de Salud Carlos III, Spain, ¹²Department of Medical
Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden, ¹³Department
Enviornmental Sciences, Vytautas Magnus University Health (CIBERSAM), Instituto de Salud Carlos III, Spain, ⁴Department of Medical
Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden, ¹³Depa
Enviornmental Sciences, Vytautas Magnus University, Lithu Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden, ²⁵Department of
Enviornmental Sciences, Vytautas Magnus University, Lithuania, ¹⁴Clinical and Experimenta
sciences, Faculty of Medicine, Univers Enviornmental Sciences, Vytautas Magnus University, Lithuania, ⁴⁴Clinical and Experimental
sciences, Faculty of Medicine, University of Southampton, UK, ¹⁵William James Center for
Research, ISPA-Instituto Universitário sciences, Faculty of Medicine, University of Southampton, UK, ²⁵William James Center for
Research, ISPA-Instituto Universitário, Portugal, ¹⁶Medical School, Royal Perth Hospital Un
The University of Western Australia, Research, ISPA-Instituto Universitário, Portugal, ¹⁹Medical School, Royal Perth Hospital Unit,,
The University of Western Australia, Austalia, ¹⁷Population and Public Health Sciences,
Environmental Health, University o Environmental Health, University of Southern California, USA, ¹⁸Department Genes and
Environment, Max-Planck-Institute of Psychiatry, Germany, ¹⁹Lifecourse Epidemiology of
Adiposity and Diabetes (LEAD) Center, Universi Environment, Max-Planck-Institute of Psychiatry, Germany, ¹⁹Lifecourse Epidemiology of
Adiposity and Diabetes (LEAD) Center, University of Colorado Anschutz Medical Campus,
²⁰Department of Medicine, Pulmonary, Critical Environment, Max-Planck-Institute of Psychiatry, Germany, ¹⁵Lifecourse Epidemiology of
Adiposity and Diabetes (LEAD) Center, University of Colorado Anschutz Medical Campus,
²⁰Department of Medicine, Pulmonary, Critical Competent of Medicine, Pulmonary, Critical Care, Allergy and Sleep, University of
California, San Francisco, USA, ²¹Center for Environmental Research and Community Heal
(CERCH), School of Public Health, University of Ca ²³Depatment of Population and Public Health Sciences, Keck Schools of Medicine, University
of Southern California, USA, ²⁴Centre for Fertility and Health, Norwegian Institute of Public
Health, Norway, ²⁵Department of (CERCH), School of Public Health, University of California, Berkeley, USA, ²²Family Medicine
and Population Health, School of Medicine, Virginia Commonwealth University, USA,
²³Depatment of Population and Public Health ²³Depatment of Population and Public Health Sciences, Keck Schools of Medicine, University
of Southern California, USA, ²⁴Centre for Fertility and Health, Norwegian Institute of Public
Health, Norway, ²⁵Department o of Southern California, USA, "Tentre for Fertility and Health, Norwegian Institute of Public
Health, Norway, ²⁵Department of Environmental Immunology, Helmholtz Centre for
Environmental Research - UFZ, Germany, ²⁶Child Health, Norway, ²⁵Department of Environmental Immunology, Helmholtz Centre for
Environmental Research - UFZ, Germany, ²⁶Children's Environmental Health Laborato
Division of Environmental Health Sciences, School of Publ Division of Environmental Health Sciences, School of Public Health, University of California,

Berkeley, USA, ²'Born in Bradford, Bradford Institute for Health Research, Bradford Teaching
Hospitals NHS Foundation Trust, UK, ²⁸Department of Medicine, Division of General Internal
Medicine, Univeristy of California Hospitals NHS Foundation Trust, UK, ^{co}Department of Medicine, Division of General Internal
Medicine, Univeristy of California, San Francisco, USA, ²⁹Department of Epidemiology,
Rollins School of Public Health, Emory Un Rollins School of Public Health, Emory University, USA, ³⁰Gangarosa Department of
Environmental Health, Rollins School of Public Health, Emory University, USA, ³¹Departme
of Biostatistics and Bioinformatics, Rollins Sc Environmental Health, Rollins School of Public Health, Emory University, USA, 31 Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, USA, 32 Public Health Practice, WES Environmental Health, Rollins School of Public Health, Emory University, USA, ³¹Department
of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, USA,
³²Public Health Practice, WESTAT, ³²Public Health Practice, WESTAT, Research Triangle Park, NC, USA, ³³Clinical and
Epidemiological Neuroscience (NeuroÈpia), Institut d'Investigació Sanitària Pere Virgili
(IISPV), Spain, ³⁴Department of Paediatrics, Epidemiological Neuroscience (NeuroÈpia), Institut d'Investigació Sanitària Pere Virgili (IISPV), Spain, ³⁴Department of Paediatrics, Dr. von Hauner Children's Hospital, Division metabolic and nutritional medicine, LMU -Medical Center Groningen, Netherlands, ³⁶Department of Clinical Sciences and Education, (IISPV), Spain, ³⁴Department of Paediatrics, Dr. von Hauner Children's Hospital, Division of
metabolic and nutritional medicine, LMU - Ludwig Maximilians Universitaet Muenchen,
Germany, ³⁵Department of Pediatric Pulmon Germany, ³⁵Department of Pediatric Pulmonology and Pediatric Allergology, Beatrix
Children's Hospital and GRIAC research institute, University of Groningen, University
Medical Center Groningen, Netherlands, ³⁶Departmen Children's Hospital and GRIAC research institute, University of Groningen, University
Medical Center Groningen, Netherlands, ³⁶Department of Clinical Sciences and Educa
Södersjukhuset,, Karolinska Institutet, Sweden, ³⁷ Medical Center Groningen, Netherlands, ³⁰Department of Clinical Sciences and Education,
Södersjukhuset,, Karolinska Institutet, Sweden, ³⁷Department of Epidemiology, University
Medical Center Groningen, University of G Södersjukhuset,, Karolinska Institutet, Sweden, ³⁷Department of Epidemiology, University
Medical Center Groningen, University of Groningen, The Netherlands, ³⁸Environment and
Health over the Lifecourse program, ISGloba Medical Center Groningen, University of Groningen, The Netherlands, ³⁶Environment and
Health over the Lifecourse program, ISGlobal, Spain, ³⁹Universitat Pompeu Fabra (UPF),
Barcelona, Spain, CIBER Epidemiología y Salud Health over the Lifecourse program, ISGlobal, Spain, ³⁻Universitat Pompeu Fabra (UPF),
Barcelona, Spain, CIBER Epidemiología y Salud Pública, Spain, ⁴⁰Department for Clinical
Science and Education, Södersjukhuset, Karo Barcelona, Spain, CIBER Epidemiología y Salud Pública, Spain, ^{-v}Department for Clinical
Science and Education, Södersjukhuset, Karolinska Institutet, Sweden, ⁴¹Health and
Biosecurity, CSIRO, Australia, ⁴²Child and ad Science and Education, Södersjukhuset, Karolinska Institutet, Sweden, ⁴-Health and
Biosecurity, CSIRO, Australia, ⁴²Child and adolescent psychiatry/psychology, Erasmu
University Medical Center Rotterdam, The Netherland Biosecurity, CSIRO, Australia, ⁴²Child and adolescent psychiatry/psychology, Erasmus MC,
University Medical Center Rotterdam, The Netherlands, ⁴³Department of Physical Health
and Ageing, Devision for Physical and Menta University Medical Center Rotterdam, The Netherlands, ⁴³Department of Physical Health
and Ageing, Devision for Physical and Mental Health, Norwegian Institute of Public Health
Norway, ⁴⁴Department of Environmental Immu Norway, ⁴⁴Department of Environmental Immunology, Helmholtz Centre for Environmental
Research - UFZ, Leipzig, Germany, ⁴⁵Human Health, Health and Biosecurity, CSIRO, Australia,
⁴⁶School of Psychological Science, Univ Research - UFZ, Leipzig, Germany, ⁻⁻Human Health, Health and Biosecurity, CSIRO, Australia,
⁴⁶School of Psychological Science, University of Bristol, UK, ⁴⁷Research Unit of Population
Health, University of Oulu, Finl ⁻"School of Psychological Science, University of Bristol, UK, ⁻"Research Unit of Population
Health, University of Oulu, Finland, ⁴⁸Department of Medicine, Pulmonary, Critical Care,
Allergy and Sleep, University of Ca Health, University of Oulu, Finland, ⁴Department of Medicine, Pulmonary, Critical Care,
Allergy and Sleep, University of California, San Francisco, San Francisco, CA, USA,
⁴⁹Department of Epidemiology, Gillings School ⁴⁹Department of Epidemiology, Gillings School of Global Public Health, University of North
Carolina at Chapel Hill, USA, ⁵⁰SAMRC Unit on Risk & Resilience in Mental Disorders, Dept c
Psychiatry & Neuroscience Institute Psychiatry & Neuroscience Institute, University of Cape Town, South Africa, ⁵¹Epidemiology
and Population Health, Stanford School of Medicine, Stanford University, USA, ⁵²Research
Department of Clinical, Education and Psychiatry & Neuroscience Institute, University of Cape Town, South Africa, ³¹Epidemiology
and Population Health, Stanford School of Medicine, Stanford University, USA, ⁵²Research
Department of Clinical, Education and and Population Health, Stanford School of Medicine, Stanford University, USA, ² Research
Department of Clinical, Education and Health Psychology, Faculty of Brain Sciences, UCL, U
⁵³Psychiatry Monash Health, Faculty of Groningen, University of Groningen, Netherlands, ⁵⁶Department of Psychology, University of
Bath, Bath, United Kingdom, ⁵⁷Department of Pediatrics, Allergy, Immunology and BMT, 32 Psychiatry Monash Health, Faculty of Medicine, Nursing and Health, Monash University, Australia, 54 Department of Epidemiology, University Medical Center Groningen, University of Groningen, Netherlands, 55 GRI Australia, ³⁴Department of Epidemiology, University Medical Center Groningen, University
of Groningen, Netherlands, ⁵⁵GRIAC Research Institute, University Medical Center
Groningen, University of Groningen, Netherlands, of Groningen, Netherlands, ³⁵GRIAC Research Institute, University Medical Center
Groningen, University of Groningen, Netherlands, ⁵⁶Department of Psychology, Un
Bath, Bath, United Kingdom, ⁵⁷Department of Pediatrics, Groningen, University of Groningen, Netherlands, ³⁰Department of Psychology, University of Bath, Bath, United Kingdom, ⁵⁷Department of Pediatrics, Allergy, Immunology and BMT, University of California, San Francisco, S Bath, Bath, United Kingdom, "Department of Pediatrics, Allergy, Immunology and BMT,
University of California, San Francisco, San Francisco, CA, USA, ⁵⁸Centre for Individualisec
Infection Medicine (CiiM), Helmholtz Centre University of California, San Francisco, San Francisco, CA, USA, ³⁰Centre for Individualised
Infection Medicine (CiiM), Helmholtz Centre for Infection Research (HZI), Hannover Medic
School (MHH), Germay, ⁵⁹TWINCORE, He School (MHH), Germay, ⁵⁹TWINCORE, Helmholtz Centre for Infection Research (HZI),
Hannover Medical School (MHH), Germany, ⁶⁰Department of Biomedical Informatics,
Univeristy of Colorado Anschutz Medical Campus, USA, ⁶¹ Hannover Medical School (MHH), Germany, ^{co}Department of Biomedical Informatics,
Univeristy of Colorado Anschutz Medical Campus, USA, ⁶¹SAMRC Unit on Child Health
of Paediatrics, University of Cape Town, South Africa, of Paediatrics, University of Cape Town, South Africa, ⁶²Epidemiology, Biostatistics, and
Environmental Health, School of Public Health, University of Memphis, USA, ⁶³Department
of Social and Behavioral Science, Harvar of Paediatrics, University of Cape Town, South Africa, ^{oc}Epidemiology, Biostatistics, and
Environmental Health, School of Public Health, University of Memphis, USA, ⁶³Departme
of Social and Behavioral Science, Harvard Environmental Health, School of Public Health, University of Memphis, USA, ^{os}Department
of Social and Behavioral Science, Harvard T. H. Chan School of Public Health, USA,
⁶⁴lmmunity Inflammation and Disease Laboratory, ⁶⁴lmmunity Inflammation and Disease Laboratory, National Institute of Environme
Health Sciences, USA, ⁶⁵Generation R Study Group, Erasmus MC, University Medic
Rotterdam, Netherlands, ⁶⁶Department of Pediatrics, Erasm Health Sciences, USA, ⁶⁵Generation R Study Group, Erasmus MC, University Medical Center
Rotterdam, Netherlands, ⁶⁶Department of Pediatrics, Erasmus MC, University Medical
2 Rotterdam, Netherlands, ⁶⁶Department of Pediatrics, Erasmus MC, University Medical Rotterdam, Netherlands, ⁶⁶Department of Pediatrics, Erasmus MC, University Medical
2

Center Rotterdam, ⁶⁷Department of Epidemiology, Erasmus MC, University Medical Center
Rotterdam, Netherlands, ⁶⁸Department of Biomedical Data Sciences, Molecular Epidemiology, Leiden University Medical Center, Netherlands Epidemiology, Leiden University Medical Center, Netherlands

Abstract
DNA methylation (DNAm) is a developmentally dynamic epigenetic process, yet we still know little about how epigenetic effects on health outcomes vary over time; whether DNAm
alterations during certain periods of development are more informative than others; and
whether epigenetic timing effects differ by o alterations during certain periods of development are more informative than others; and
whether epigenetic timing effects differ by outcome. To address these questions, we
applied longitudinal meta-regression to published whether epigenetic timing effects differ by outcome. To address these questions, we
applied longitudinal meta-regression to published meta-analyses from the PACE consortiu
that examine DNAm at multiple time points (prospec applied longitudinal meta-regression to published meta-analyses from the PACE consthat examine DNAm at multiple time points (prospectively at birth and cross-sectiona childhood) in relation to the same child outcome (ADHD, that examine DNAm at multiple time points (prospectively at birth and cross-sectionally in
childhood) in relation to the same child outcome (ADHD, general psychopathology, sleep,
BMI, asthma). Our findings reveal three new childhood) in relation to the same child outcome (ADHD, general psychopathology, sleep,
BMI, asthma). Our findings reveal three new insights: (i) across outcomes, effects sizes are
larger when DNAm is measured in childhood BMI, asthma). Our findings reveal three new insights: (i) across outcomes, effects sizes are larger when DNAm is measured in childhood compared to at birth; (ii) higher effect sizes do
not necessarily translate into more significant findings, as associations also become noisier
in childhood for most outcomes (i.e. larger when the cessarily translate into more significant findings, as associations also become noisier
in childhood for most outcomes (i.e. showing larger standard errors); and (iii) DNAm signals
are highly time-specific in childhood for most outcomes (i.e. showing larger standard errors); and (iii) DNAm signals
are highly time-specific while showing pleiotropy across health outcomes. are highly time-specific while showing pleiotropy across health outcomes. are highly time-specific while showing pleiotropy across health outcomes. The sh

Introduction

DNAm is influenced by both genetic 1,2 and environmental factors, beginning in utero (e.g.
maternal smoking, 3 stressful life events⁴, air pollution, 5 or physical activity 6). Alterations in
DNAm have also DNAm is influenced by both genetic⁺.² and environmental factors, beginning in utero (e.g.
maternal smoking,³ stressful life events⁴, air pollution,⁵ or physical activity⁶). Alterations in
DNAm have also been li maternal smoking," stressful life events", air pollution," or physical activity"
DNAm have also been linked to a wide range of health outcomes across chi
asthma⁷, attention-deficit/hyperactivity disorder (ADHD)⁸, and b DNAm have also been linked to a wide range of health outcomes across childhood, including
asthma⁷, attention-deficit/hyperactivity disorder (ADHD)⁸, and body mass index (BMI)⁹.
Together, these properties make DNAm a Together, these properties make DNAm an attractive biological process in the search for
both biomarkers and mediators of disease risk. asthma', attention-deficit/hyperactivity disorder (ADHD)", and body mass index (BMI)"
Together, these properties make DNAm an attractive biological process in the search for
both biomarkers and mediators of disease risk.
D

. Together, these properties make 2 is much attractive biological process in the search for both biomarkers and mediators of disease risk.

DNAm is highly dynamic during development – a property that makes it particular

int DNAm is highly dynamic during develop
interesting, but also challenging to study. Mulde
sites show changes in methylation from birth to
trajectory. Furthermore, in around a third of DN interesting, but also challenging to study. Mulder et al.¹⁰ estimated that over half of DNAm sites show changes in methylation from birth to 18 years of age, often following a non-linear trajectory. Furthermore, in arou interesting, but also challenging to study. Mulder et al.³⁰ estimated that over half of DNAm
sites show changes in methylation from birth to 18 years of age, often following a non-linea
trajectory. Furthermore, in around Frajectory. Furthermore, in around a third of DNAm sites, the degree of change varies
between individuals, perhaps reflecting exposure to different postnatal environments,
genetic variation or stochastic processes.¹¹ Yet the individuals, perhaps reflecting exposure to different postnatal environments,
genetic variation or stochastic processes.¹¹ Yet, most observational studies linking DN,
health phenotypes measure DNAm only once.¹² Thu genetic variation or stochastic processes.¹¹ Yet, most observational studies linking DNA
health phenotypes measure DNAm only once.¹² Thus, it is largely unknown (i) whether
relationship between DNAm and health outcomes health phenotypes measure DNAm only once.¹² Thus, it is largely unknown (i) whether the relationship between DNAm and health outcomes varies across development (ii) at which developmental periods DNAm profiles could be m relationship between DNAm and health outcomes varies across development (ii) at which
developmental periods DNAm profiles could be most informative for a given health
outcome, and (iii) to what extent DNAm-health associati developmental periods DNAm profiles could be most informative for a given health

outcome, and (iii) to what extent DNAm-health associations at one time point can b
generalized to other time points.
Population-based cohorts have emerged as a powerful tool for the study of I
health associations, due to t generalized to other time points.

Population-based cohorts have emerged as a powerful tool for the study of DN

health associations, due to their relatively large sample sizes and longitudinal follow-u

most pediatric pop Population-based cohorts
health associations, due to their r
most pediatric population studies
and associated with a child outco point as the child outcome (i.e. cross-sectional EWAS). Theoretical arguments exist for most pediatric population studies, DNAm is either measured in cord blood samples at birth
and associated with a child outcome at a later time point (i.e. prospective epigenome-wide
association study [EWAS]) *or* DNAm is me and associated with a child outcome at a later time point (i.e. prospective epigenome-wide
association study [EWAS]) *or* DNAm is measured from a blood sample at the same time
point as the child outcome (i.e. cross-section association study [EWAS]) *or* DNAm is measured from a blood sample at the same time
point as the child outcome (i.e. cross-sectional EWAS). Theoretical arguments exist for
either design. On the one hand, DNAm measured in point as the child outcome (i.e. cross-sectional EWAS). Theoretical arguments exist for
either design. On the one hand, DNAm measured in cord blood at birth coincides with a
developmentally sensitive period and may reflect poither design. On the one hand, DNAm measured in cord blood at birth coincides with developmentally sensitive period and may reflect causal effects of genetic and *in utero*
environmental factors that can influence risk o developmentally sensitive period and may reflect causal effects of genetic and *in utero*
environmental factors that can influence risk of later outcomes.¹³ Furthermore, reverse
causation scenarios are less likely, given environmental factors that can influence risk of later outcomes.¹³ Furthermore, reverse
causation scenarios are less likely, given that outcomes in childhood are unlikely to affer
methylation profiles at birth. However, environmental factors that can influence risk of later outcomes." Furthermore, reverse
causation scenarios are less likely, given that outcomes in childhood are unlikely to affec
methylation profiles at birth. However, cro causation profiles at birth. However, cross-sectional EWASs during childhood may result in a stronger association signal, due to the temporal proximity between predictor and outcome, a larger accumulation of environmental in a stronger association signal, due to the temporal proximity between predictor and
outcome, a larger accumulation of environmental effects (prenatal and postnatal), or the
potential for DNAm patterns in childhood to ref outcome, a larger accumulation of environmental effects (prenatal and postnatal), or t
potential for DNAm patterns in childhood to reflect both a cause and consequence of $|$
health (reverse causality). Cord and peripheral potential for DNAm patterns in childhood to reflect both a cause and consequence of poor
health (reverse causality). Cord and peripheral blood also represent different tissues, with
different cell compositions (e.g., nucle potential for the distribution of the distribution in the different tissues, with different cell compositions (e.g., nucleated red blood cells being present in cord, but not peripheral blood), which may contribute to diffe different cell compositions (e.g., nucleated red blood cells being present in cord, but not
peripheral blood), which may contribute to differences in associations of DNAm with healt
outcomes.¹⁴ However, it is challenging peripheral blood), which may contribute to differences in associations of DNAm with hea
outcomes.¹⁴ However, it is challenging to fully separate the influence of tissue versus
timing, as for example cord blood is only av performes.¹⁴ However, it is challenging to fully separate the influence of tissue versus
timing, as for example cord blood is only available at birth, and early cell-type changes are in
part developmentally regulated.¹⁴ outcomes.⁴⁴ However, it is challenging to fully separate the influence of tissue versus
timing, as for example cord blood is only available at birth, and early cell-type changes
part developmentally regulated.^{14,15} t_{part} developmentally regulated.^{14,15} part developmentally regulated.^{14,15}

Recently, the Pregnancy And Childhood Epigenetics (PACE) Consortium²⁶ published
Iti-cohort EWAS meta-analyses that investigated DNAm using *both designs* in
16 the same child outcome, spanning mental and physical health Figure multi-cohort EWAS meta-analyses that investigated DNAM using both designs in
relation to the same child outcome, spanning mental and physical health domains, na
ADHD,⁸ general psychopathology (measured as a latent ADHD, 8 general psychopathology (measured as a latent factor; GPF), 17 sleep duration, 18
body mass index (BMI) 9 and asthma⁷. Results from these previous studies can be
summarized as follows (Table 1): for body mass index (BMI)⁹ and asthma⁷. Results from these previous studies can be
summarized as follows (Table 1): for ADHD, there were more hits for DNAm at birth rather general psychopathology (measured as a latent factor; GPF),²⁷ sleep duration,²⁹
ass index (BMI)⁹ and asthma⁷. Results from these previous studies can be
rized as follows (Table 1): for ADHD, there were more hits f body mass index (BMI)° and asthma'. Results from these previous studies can be
summarized as follows (Table 1): for ADHD, there were more hits for DNAm at bir
than in childhood (i.e prospective EWAS showed more hits than c than in childhood (i.e prospective EWAS showed more hits than cross-sectional EWAS);
whereas the opposite was true for BMI and asthma (i.e. prospective EWAS showed fewer
hits than cross-sectional EWAS). For GPF and sleep, whereas the opposite was true for BMI and asthma (i.e. prospective EWAS showed fewer
hits than cross-sectional EWAS). For GPF and sleep, results were mostly null at either time
point. Together, these findings point to the hits than cross-sectional EWAS). For GPF and sleep, results were mostly null at either time
point. Together, these findings point to the potential existence of epigenetic 'timing effect:
on child health.
Despite these intr point. Together, these findings point to the potential existence of epigenetic 'timing effects'

quantify temporal changes of DNAm-health associations. Addressing this aim would require on children
Despite t
identification of
quantify tempor
specific analyses Example intervalues intervalues in the studies intriguing cation of health-relevant DNAm sites at each time point, rather than system y temporal changes of DNAm-health associations. Addressing this aim wo analyses that wer quantify temporal changes of DNAm-health associations. Addressing this aim would require
specific analyses that were not originally performed, including quantitatively comparing
effect sizes between time points, accounting specific analyses that were not originally performed, including quantitatively comparing
effect sizes between time points, accounting for sample size imbalances that affect
statistical power per time point, and examining p effect sizes between time points, accounting for sample size imbalances that affect
statistical power per time point, and examining potential statistical and biological factors
contributing to temporal differences in DNAmstatistical power per time point, and examining potential statistical and biological factors statistical point, and examining potential and alternative contributing to temporal differences in DNAm-health associations. Furthermore, no
comparison has been performed *across* studies, to establish how temporal pattern comparison has been performed *across* studies, to establish how temporal patterns may
vary for different child health outcomes, and whether methylation signals for one outcon
correlate with that for other outcomes (i.e., comparison has been performed across studies, to establish how temporal patterns may
vary for different child health outcomes, and whether methylation signals for one outcon
correlate with that for other outcomes (i.e., in

correlate with that for other outcomes (i.e., indicating pleiotropy/shared epigenetic effects)
Here, we re-analyzed the five PACE meta-analyses on ADHD, GPF, sleep, BMI and
asthma (N_{pooled}=2178-4641, 26 cohorts) to expl Here, we re-analyzed the five PACE meta-analyses on ADHD, GPF, sleep, BMI and
asthma (N_{pooled}=2178-4641, 26 cohorts) to explore timing effects on DNAm-health
associations during development. For each outcome, we integrat $(N_{\text{pooled}}=2178-4641, 26 \text{ cohorts})$ to explore timing effects on DNAm-health
tions during development. For each outcome, we integrated results from the
tive EWAS (cord blood DNAm at birth) and the cross-sectional EWAS (whole bl associations during development. For each outcome, we integrated results from the
prospective EWAS (cord blood DNAm at birth) and the cross-sectional EWAS (whole blood
DNAm in childhood) into a longitudinal meta-regression prospective EWAS (cord blood DNAm at birth) and the cross-sectional EWAS (whole blood prospective EWAS (corresponding matrix of the cross-section model. This model enabled us to
systematically quantify changes in effect sizes and statistical significance between time
points, and also explore a range of fact systematically quantify changes in effect sizes and statistical significance between time
points, and also explore a range of factors that may contribute to the observed temporal
trends. We then performed correlation analy systems, and also explore a range of factors that may contribute to the observed temporatrends. We then performed correlation analyses to estimate the consistency of DNAm associations *between time points* (i.e. in order t points, and also explore a range of factors indicate, point and the consistency of DNAm
associations *between time points* (i.e. in order to assess generalizability of epigenetic sign
from one time point to another) and *a* associations *between time points* (i.e. in order to assess generalizability of epigenetic s
from one time point to another) and *across child health outcomes* (i.e. to explore prese
of shared DNAm associations). associations between time points (i.e. in order to assess generalizability of epigenetic signals
from one time point to another) and *across child health outcomes* (i.e. to explore presence
of shared DNAm associations). from one time point to another) and across child health outcomes (i.e. to explore presence
of shared DNAm associations). of shared DNAm associations).

Results

How do EWAS effect sizes change from birth to childhood?
We applied multilevel meta-regression models in which regression coefficients (β) from the We applica multilevel meta-regression in which regressed on a
prospective and cross-sectional EWAS were pooled across cohorts and regressed on a
variable indicating whether the estimate pertains to birth or childhood DNAm provide indicating whether the estimate pertains to birth or childhood DNAm. This more therefore quantified the DNAm associations at birth, in childhood, as well as the difference in associations between time points. β variable indicating whether the estimate pertains to birth or childhood DNAm. This model
therefore quantified the DNAm associations at birth, in childhood, as well as the difference
in associations between time points. $\$ in associations between time points. β here represents the difference in child health
outcomes in standard deviations (SD) between no to full methylation in the case of
continuous variables or as odds ratio for the cat outcomes in standard deviations (SD) between no to full methylation in the case of
continuous variables or as odds ratio for the categorical outcome asthma. We focuse
effect sizes as defined by the absolute regression co continuous variables or as odds ratio for the categorical outcome asthma. We focus
effect sizes as defined by the absolute regression coefficient at birth $|\beta_{\text{birth}}|$ or in ch
 $|\beta_{\text{childhood}}|$. Furthermore, we characterized g effect sizes as defined by the absolute regression coefficient at birth $|\beta_{\text{birth}}|$ or in childhoo $|\beta_{\text{childhood}}|$. Furthermore, we characterized global trends defined by mean statistics, averaged across all autosomal DNAm s $|\beta_{\text{childhood}}|$. Furthermore, we characterized global trends defined by mean statistics,
averaged across all autosomal DNAm sites tested. Tables S1 and S2 show an overview of
included cohorts and the overlap between time poi averaged across all autosomal DNAm sites tested. Tables S1 and S2 show an overview of

phenotypes, 10% higher methylation was associated with a 0.10SD outcome difference. For For DNAm at birth, mean effect sizes across DNAm sites ranged
1.23 (GPF) for continuous measures (Table 2; Figures 1,2,S1,S2). Avera
phenotypes, 10% higher methylation was associated with a 0.10SD out
asthma, mean log(odds FF) for continuous measures (Table 2; Figures 1,2,S1,S2). Averaged across
ypes, 10% higher methylation was associated with a 0.10SD outcome difference. Fo
, mean log(odds) were 2.70, which corresponds to a 10% methylation phenotypes, 10% higher methylation was associated with a 0.10SD outcome different asthma, mean log(odds) were 2.70, which corresponds to a 10% methylation different being associated with 1.30 lower/higher odds of receivin

phenotypes, 10% higher acts and the corresponds to a 10% methylation difference
being associated with 1.30 lower/higher odds of receiving an asthma diagnosis.
Compared to DNAm at birth, mean effect sizes for DNAm in childh being associated with 1.30 lower/higher odds of receiving an asthma diagnosis.
Compared to DNAm at birth, mean effect sizes for DNAm in childhood were
consistently *higher* across all tested outcomes (Table 2,3; Figure 1,2 Compared to DNAm at birth, mean effect sizes for DNAm in childhood w
consistently *higher* across all tested outcomes (Table 2,3; Figure 1,2,S1,S2), rang
1.10 (BMI) to 1.59 (Sleep) for continuous outcomes and an log(odds) ently *higher* across all tested outcomes (Table 2,3; Figure 1,2,S1,S2), ranging
MI) to 1.59 (Sleep) for continuous outcomes and an log(odds) of 2.94 (odds r
r asthma. When quantifying this *difference* in effect sizes be 1.10 (BMI) to 1.59 (Sleep) for continuous outcomes and an log(odds) of 2.94 (odds ratio of 1.34) for asthma. When quantifying this *difference* in effect sizes between birth and childhood, the smallest mean difference was 1.34) for asthma. When quantifying this *difference* in effect sizes between birth and
childhood, the smallest mean difference was observed for BMI (| $\overline{\beta}_{\text{childhood}}$ =1.10 vs
| $\overline{\beta}_{\text{birth}}$ =0.77) and the largest differe 1.34) for asthma. When quantifying this difference in effect sizes between birth and
childhood, the smallest mean difference was observed for BMI ($|\overline{\beta}_{\text{childhood}}|$ =1.10 vs
 $|\overline{\beta}_{\text{birth}}|$ =0.77) and the largest difference fo $|\overline{\beta}_{\text{birth}}|$ =0.77) and the largest difference for sleep ($|\overline{\beta}_{\text{childhood}}|$ =1.59 vs $|\overline{\beta}_{\text{birth}}|$ =0.97).
Aggregating across continuous outcomes, mean effect sizes were 40% higher in childhood,
with an outcome difference o | β_{birth}|=0.77) and the largest difference for sleep (| β_{childhood}|=1.59 vs | β_{birth}|=0.97).
Aggregating across continuous outcomes, mean effect sizes were 40% higher in childho
with an outcome difference of 0.14SD With an outcome difference of 0.14SD per 10% methylation. For asthma, the odds ratio
increased from 1.30 to 1.34. Table S3 shows effect size comparisons across percentiles.
While these effect size figures provide a global

increased from 1.30 to 1.34. Table S3 shows effect size comparisons across percentiles.
While these effect size figures provide a global view of genome-wide association
change, they do not take into account statistical pre While these effect size figures provide a global view of genome-wide association
change, they do not take into account statistical precision (i.e., standard error (SE)). Ano
way to quantify DNAm differences at birth versus While these encounted a global view of general view of these encounts and the provide quantify DNAm differences at birth versus in childhood is by counting the number which DNAm effect sizes increase or decrease over time way to quantify DNAm differences at birth versus in childhood is by counting the number of
sites at which DNAm effect sizes increase or decrease over time based on a chosen p-value
threshold of change. Among probes that sh sites at which DNAm effect sizes increase or decrease over time based on a chosen p-value
threshold of change. Among probes that showed at least a nominally significant difference
between time points, there were 1.5-3x mor sites at which DNAm effect sizes at more probes that showed at least a nominally significant difference
between time points, there were 1.5-3x more DNAm sites with a larger as opposed to
smaller effect size in childhood ac between time points, there were 1.5-3x more DNAm sites with a larger as opposed to
smaller effect size in childhood across health outcomes. (Table 2, Figures 2,S1-S4). To test
the robustness of this approach, we also exami smaller effect size in childhood across health outcomes. (Table 2, Figures 2,S1-S4). To the robustness of this approach, we also examined the ratio of DNAm sites that show a effect size increase vs decreases over time acro smaller effect size increase vs decreases over time across different change p-value thresholds from
no thresholding to p<0.0001 (Figure S4). We observed that the ratio is always positive (i.e.
more DNAm showing an increase effect size increase vs decreases over time across different change p-value thresholds fro
no thresholding to p<0.0001 (Figure S4). We observed that the ratio is always positive (i.e
more DNAm showing an increase in effect no thresholding to p<0.0001 (Figure S4). We observed that the ratio is always positive (i.e.
more DNAm showing an increase in effect size over time) — a trend that becomes stronger
as the threshold becomes more stringent (more DNAm showing an increase in effect size over time) – a trend that becomes stronger more DNAm showing an increase in effect size over time) – a trend that becomes stronger as the threshold becomes more stringent (lower p-values).

amined the direction of association with the health outcome, and whether this
in was consistent or not across time points. The most common pattern was a null or
ffect at birth, followed by a positive association in childho direction was consistent or not across time points. The most common pattern was a numall effect at birth, followed by a positive association in childhood (Table S3). This ap to all outcomes, except BMI. Here the most frequ and effect at birth, followed by a positive association in childhood (Table S3). This applied
to all outcomes, except BMI. Here the most frequent pattern was a switch from a positive
association at birth to a negative asso small effect at birth, followed by a positive association in childhood (Table S3). This applied
to all outcomes, except BMI. Here the most frequent pattern was a switch from a positive
association at birth to a negative a

association at birth to a negative association in childhood.

Three DNAm sites showed a genome-wide significant change in association.

Cg11945228 in *BRD2* had no association with GPF at birth ($\beta_{\text{birth}} = 5.28$, SE=3.76, Three DNAm sites showed a genome-wide significa
Cg11945228 in *BRD2* had no association with GPF at birth is
became genome-wide significantly associated in childhood
p=8.58*10⁻⁸), a significant change (p=7.68*10⁻⁸). S Cg11945228 in *BRD2* had no association with GPF at birth (β_{birth} =5.28, SE=3.76, p=0.16), but
became genome-wide significantly associated in childhood (β_{children} =-37.00, SE=6.91,
p=8.58*10⁻⁸), a significant change $p=8.58*10⁻⁸$), a significant change ($p=7.68*10⁻⁸$). Similarly, cg10644885 in *ACP5* had a significant change ($p=2.25*10⁻⁸$) from no association with asthma at birth ($β_{\text{birth}}$ =-0.56, SE=1.19, $p=0.64$) p=8.58*10 °), a significant change (p=7.68*10 °). Similarly, cg10644885 in *ACP5* had a
significant change (p=2.25*10⁻⁸) from no association with asthma at birth (β_{birth} =-0.56
SE=1.19, p=0.64) to genome-wide signifi SE=1.19, p=0.64) to genome-wide significance in childhood (β_{childhood}=-15.00, SE=2.29,
p=5.57*10⁻¹¹). In addition, cg22708087 in *FRY* changed from a positive association with
asthma at birth (β_{birth}=7.47, SE=1.80, $p=5.57*10^{-11}$). In addition, cg22708087 in *FRY* changed from a positive association wit asthma at birth (β_{birth}=7.47, SE=1.80, p=3.42*10⁻⁵) to a negative association in childhood (βchildhood=-12.64, SE=3.32, p=1.4 p=5.57*10 ⁻⁻). In addition, cg22708087 in FRY changed from a positive association with
asthma at birth (β_{birth}=7.47, SE=1.80, p=3.42*10⁻⁵) to a negative association in childhood
(β_{childhood}=-12.64, SE=3.32, p=1.44 asthma at birth (β_{birth}=7.47, SE=1.80, p=3.42*10~) to a negative association in childhood
(β_{childhood}=-12.64, SE=3.32, p=1.44*10⁻⁴). This change was genome-wide significant
(p=1.06*10⁻⁷). For all three genome-wide (β_{childhood}=-12.64, SE=3.32, p=1.44*10⁻⁺). This change was genome-wide significant
(p=1.06*10⁻⁷). For all three genome-wide significantly changing DNAm sites, absolu
sizes were larger in childhood.
Do changes in eff

(p=1.06*10⁻'). For all three genome-wide significantly changing DNAm sites, absolute effect
sizes were larger in childhood.
Do changes in effect size correspond with changes in the ability to identify significant
associa sizes were larger in childre car
Do changes in effect size cor
associations?
While mean effect sizes were r Do changes in effect size correspond with changes in the ability to identify significant associations?
While mean effect sizes were robustly larger for DNAm in childhood compared to DNAm at

 $\begin{array}{c} 1 \\ 1 \\ 0 \\ 1 \end{array}$ birth for all outcomes, this did not necessarily translate into more significant associations, as
quantified by higher Z test-statistics (equal to lower p-values) (see also Tables 2,3 and
Figures 1,2,51,52).
ADHD. DNAm a quantified by higher Z test-statistics (equal to lower p-values) (see also Tables 2,3 and

significant associations at all tested thresholds (Bonferroni, FDR, nominal). Despite an
increase in effect sizes from birth to childhood, the mean Z-value dropped (1.02 at birth vs evidenced by a mean Z-value of 1.02 and the identification of the largest number of 0.78 in childhood). No CpG site was identified as genome-wide significant in the crossexistence and associations at all tested thresholds (Bonferroni, FDR, nominal). Despite a
increase in effect sizes from birth to childhood, the mean Z-value dropped (1.02 at b
0.78 in childhood). No CpG site was identified increase in effect sizes from birth to childhood, the mean Z-value dropped (1.02 at birt
0.78 in childhood). No CpG site was identified as genome-wide significant in the cross-
sectional EWAS and the number of nominally s 0.78 in childhood). No CpG site was identified as genome-wide significant in the cross-
sectional EWAS and the number of nominally significant sites was 3-fold lower ($n_{cpg\text{-birth}}$
=57,339 vs $n_{cpg\text{-children}}$ =19,034).
GPF. The

no childhood). No childhood is childhood as genome-wide signified as genome-wide significant in the cross-control of control of contro sectional EWAS and the number of nominally significant sites was 3-fold lower (n_{cpg-birth}
=57,339 vs n_{cpg-childhood}=19,034).
GPF. The mean Z-value remained constant at 0.78 for both time points, and the
number of no =57,339 vs n_{cpg-childhood}=19,034).
 GPF . The mean Z-value

number of nominally significal

significance at birth, and one I

in childhood. GPT. The mean Z-value remained constant at 0.78 for both time points, and the
r of nominally significant sites remained similar. No DNAm site reached genome-
ance at birth, and one DNAm site reached genome-wide significanc

number of nominally significance at birth, and one DNAm site reached genome-wide significance when assessed
in childhood.
Sleep. Mean Z-values for sleep did not differ between time-points and the number of
nominally signif in childhood.
Sleep. Mean Z-values for sleep did not differ between time-points and the number o
nominally significant sites remained similar, with no genome-wide significant hits at either
time point. Sleep.

nominally sign

time point.

BMI. F Sleep. Wean Z-values for sleep did not differ between time-points and the number of
Ily significant sites remained similar, with no genome-wide significant hits at either
int.
BMI. For BMI the higher DNAm effect sizes in c

time point.

BMI. For BMI the higher DNAm effect sizes in childhood corresponded with a higher

statistical significance. This is also reflected by the doubling of nominally significant time point.
BMI
statistical si BMI. For BMI the higher DNAM effect sizes in childhood corresponded with a higher
cal significance. This is also reflected by the doubling of nominally significant
8 statistical significance. This is also reflected by the doubling of normally significant
 $\frac{1}{8}$

genome-wide hits in childhood, but not at birth.
Asthma. The mean Z-values and number of nominally significant sites were
somewhat larger at birth than childhood. While this reflects the genome-wide trend, i
important to e Asthma. The mean Z-values and number of
somewhat larger at birth than childhood. While t
important to emphasize that the number of prob
much larger for DNAm in childhood (66 hits in th Asthma. The mean 2-values and number of nominally significant sites were
hat larger at birth than childhood. While this reflects the genome-wide tren
ant to emphasize that the number of probes with genome-wide significance something the summand childhood.

Simportant to emphasize that the number of probes with genome-wide significance was

much larger for DNAm in childhood (66 hits in the cross-sectional EWAS vs 0 hits in the

prospective EW much larger for DNAm in childhood (66 hits in the cross-sectional EWAS vs 0 hits in the
prospective EWAS).
What explains these outcome-specific patterns?
We searched potential explanations for why statistical significance

What explains these outcome-specific patterns?

prospective EWAS).

What explains these outcome-specific patterns?

We searched potential explanations for why statistical significance did not

necessarily increase over time, or even decreased for specific outcomes, desp what explain

We searched

necessarily increase

increases. Z- and the increases. Z- and therefore p-values represent the ratio between effect size and statistical
uncertainty. We found that standard errors (SE) increased from birth to childhood either to
a disproportionately larger (ADHD, as increases. Z- and therefore p-values represent the ratio between effect size and statistical
uncertainty. We found that standard errors (SE) increased from birth to childhood either to
a disproportionately larger (ADHD, as increases. The found that standard errors (SE) increased from birth to childhood either to
a disproportionately larger (ADHD, asthma) or similar (GPF, sleep) extent as the effect size
increased (Tables 2,3), i.e. only for a disproportionately larger (ADHD, asthma) or similar (GPF, sleep) extent as the effect size
increased (Tables 2,3), i.e. only for BMI did the increase in effect size outpace the increase in
SE leading on average to more s

increased (Tables 2,3), i.e. only for BMI did the increase in effect size outpace the increase
SE leading on average to more statistical significance.
Next, we investigated potential sources for the SE increase. The first SE leading on average to more statistical significance.
Next, we investigated potential sources for the SE increase. The first was sample size,
which was unequal between EWAS time points for some outcomes. For GPF, total s SE READING STREET CONTROLLED INTERNATION NEXT, NEXT, WE investigated potential sources for the
which was unequal between EWAS time points for sor
size was very similar, and for asthma the number of ca
points. However, espe Next, we investigated potential sources for the SE increase. The first was sample size,
vas unequal between EWAS time points for some outcomes. For GPF, total sample
s very similar, and for asthma the number of cases was a measured in childhood, which increases SE. In sensitivity analyses we removed cohorts
(Table S1) to achieve equal sample sizes between time points. Interestingly, patterns points. However, especially for sleep and BMI, sample sizes were much lower for DNAm
measured in childhood, which increases SE. In sensitivity analyses we removed cohorts
(Table S1) to achieve equal sample sizes between ti measured in childhood, which increases SE. In sensitivity analyses we removed cohorts
(Table S1) to achieve equal sample sizes between time points. Interestingly, patterns
remained largely the same, i.e., with only BMI sho measured in children in children in children increases the control of table S1) to achieve equal sample sizes between time points. Interestingly, patterns
remained largely the same, i.e., with only BMI showing correspondin effect sizes and statistical significance over time (Table S4).
Second, we examined *between-study heterogeneity*, which tends to increase SE. We

The S1) to achieve the sample sample is controlled to the sample of the same offect sizes and statistical significance over time (Table S4).
Second, we examined *between-study heterogeneity*, which tends to increase S1) Se assessment periods. Indeed, we generally observed an increase in between-study
heterogeneity for all outcomes over time, except for GPF (Table S5), suggesting that
partly influence differences in EWAS signal between time p fit random slope models, allowing for different amounts of heterogeneity at different DNAm
assessment periods. Indeed, we generally observed an increase in between-study
heterogeneity for all outcomes over time, except for fit random slope models, indeed, we generally observed an increase in between-study
heterogeneity for all outcomes over time, except for GPF (Table S5), suggesting that it may
partly influence differences in EWAS signal be heterogeneity for all outcomes over time, except for GPF (Table S5), suggesting the
partly influence differences in EWAS signal between time points. We examined thi
possibility by re-computing meta-regression analyses usin partly influence differences in EWAS signal between time points. We examined this
possibility by re-computing meta-regression analyses using a single cohort. We chose
ALSPAC, as it was the largest cohort contributing to al possibility by re-computing meta-regression analyses using a single cohort. We chose
ALSPAC, as it was the largest cohort contributing to all analyses with similar sample
birth and childhood. Overall, the pattern of result possibility of the largest cohort contributing to all analyses with similar sample size ALSPAC, as it was the largest cohort contributing to all analyses with similar sample size birth and childhood. Overall, the pattern o ALSPAC, and the largest contribution allows to all analytical corresponded to the meta-
analytical results for all outcomes, suggesting that observed temporal differences are
unlikely to be solely explained by EWAS cohort analytical results for all outcomes, suggesting that observed temporal differences are
unlikely to be solely explained by EWAS cohort composition in the meta-analyses.
How do epigenetic signals correlate across time points

dow do epigenetic signals correlate across time points and child outcomes? How do epigenetic signals correlate across time points and child outcomes?

unlikely to be solely explained by EWAS consistency of the meta-analyses.
To test the consistency of epigenetic associations over time and across outcomes,
computed spearman correlations (rs) between the regression coeffic $\frac{1}{\sqrt{2}}$ computed spearman correlations (r_s) between the regression coefficients of all time points
and outcomes (Figure 3). For ADHD, estimates at birth correlated modestly with those in
childhood (r_s =0.31). For all other out and outcomes (Figure 3). For ADHD, estimates at birth correlated modestly with those in childhood $(r_s=0.31)$. For all other outcomes, estimates between time points were
uncorrelated $(r_s<0.08)$. The coefficients in the ADHD analysis correlated most with the
coefficients for other outcomes. For instance, the E childhood (rs=0.31). For all other outcomes, estimates between time points were
uncorrelated (rs<0.08). The coefficients in the ADHD analysis correlated most with
coefficients for other outcomes. For instance, the EWAS sig coefficients for other outcomes. For instance, the EWAS signal at birth for ADHD was
9 coefficients for other outcomes. For instance, the EWAS signal at birth for ADHD was signal at θ

positively correlated with the signal at birth for GPF (r_s =0.35) and asthma (r_s =0.21), but
negatively correlated with the EWAS signal in childhood of BMI (r_s =-0.18) and asthma (r_s =-
0.16).
Overlap between cohorts

negatively correlated with the EWAS signal in childhood of BMI (rs=-0.18) and asthma (rs=-0.16).

Overlap between cohorts contributing to analyses at the same time point tended to

be larger than between time points. To te ---,
be larg
correl:
(as the be larger than between time points (Table S2). This may have led to an underestimation of
correlations between time points. To test this, we re-ran correlation analyses within ALSPAC
(as the largest cohort with repeated D correlations between time points. To test this, we re-ran correlation analyses within ALSPA
(as the largest cohort with repeated DNAm measures), and found that between time-point
correlations remained low for GPF, sleep a (as the largest cohort with repeated DNAm measures), and found that between time-point
correlations remained low for GPF, sleep and BMI (r_s <0.12) and modest for ADHD (r_s =0.25)
(Figure S5). Asthma could not be tested, (as the largest construction repeated DMAMI (rs<0.12) and modest for ADHD (rs=0.25)
(Figure S5). Asthma could not be tested, due to unavailable analyses in childhood.
Which biological pathways are involved in health-relate

correlations remained low for GPT, sleep and BMI (rsso.12) and modest for ADHD (rs=0.25)
(Figure S5). Asthma could not be tested, due to unavailable analyses in childhood.
Which biological pathways are involved in health-r (Figure S
Which biological pathways are involved in health-related DNAm patterns that
from birth to childhood?
We performed gene ontology enrichment analyses to probe the potential b Which biological pathways are involved in health-related DNAm patterns that change from birth to childhood?
We performed gene ontology enrichment analyses to probe the potential biological

relevance of temporal changes in DNAm-health associations and to examine the possibility
that we may be mainly picking up tissue differences (as opposed to developmental/
temporal differences) between birth and childhood. relevance of temporal changes in Drama changes in Drama in the positions and the position,
temporal differences) between birth and childhood. We selected sites that (i) were
nominally associated with an outcome at either t temporal differences) between birth and childhood. We selected sites that (i) were
nominally associated with an outcome at either time point *and* (ii) showed at least
nominally significant *change* in associations from bi temporal anti-carry activities that and childrences the childhood. Notably for AD
nominally significant *change* in associations from birth to childhood. Notably for AD
and sleep, neural features stand out among the top 10 nominally significant *change* in associations from birth to childhood. Notably for AD
and sleep, neural features stand out among the top 10 pathways (e.g. cerebral cort
neuron development, enrichment for synapses and dend nominally significant change in associations from birth to childhood. Notably for ADHD, GPT
and sleep, neural features stand out among the top 10 pathways (e.g. cerebral cortex and
neuron development, enrichment for synaps neuron development, enrichment for synapses and dendrites, Table 4). While neural
pathways also rank highly for BMI and asthma, other more general cell processes such as
morphogenesis are prominently represented. However, neuron accompanies, enrichment for symptoce and actionize, there as a pathways also rank highly for BMI and asthma, other more general cell processes suc
morphogenesis are prominently represented. However, no pathway was s pathways and cannonging the BMI and asthma, onder more general cell processes and morphogenesis are prominently represented. However, no pathway was significant after adjustment for multiple testing of all 22,560 GO terms. morphogenesis are prominently represented. However, the pathway material and adjustment for multiple testing of all 22,560 GO terms. See Tables S6-S11 for all pathways
with nominal significance. adjustment for multiple testing of all 22,560 Go terms. See Tables S60 Go terms. See Tables S6-S11 for all path
with nominal significance. with non-nominal significance.
The nominal significance of the nominal significance.

Discussion
We performed the first systematic comparison of DNAm-health associations at two different time points during development (birth and childhood) on child outcomes spanning
mental and physical domains, by jointly reanalyzing published multi-cohort EWAS meta-
analyses from the PACE Consortium. Our finding mental and physical domains, by jointly reanalyzing published multi-cohort EWAS meta-
analyses from the PACE Consortium. Our findings lend three important new insights: 1.
Effect sizes tend to be larger when DNAm is measur me are necessedam, lead to more significant multige, 3. DNAm signals are largely alcohort between time points, but they correlate across outcomes, indicating shared associations with child health.
Which is distinct that th analyses from the PACE Constraining of the International International International Effect sizes tend to be larger when DNAm is measured in childhood compared to at birtleven though EWAS effect sizes consistently increase Even though EWAS effect sizes consistently increase over time for all outcomes examined,
this did not necessarily lead to more significant findings; 3. DNAm signals are largely distinct
between time points, but they correl this did not necessarily lead to more significant findings; 3. DNAm signals are largely distinc
between time points, but they correlate across outcomes, indicating shared associations
with child health. with child health.
Insight 1. EWAS effect sizes increase over time for all child health outcomes
Que first lieu finding is that associations associations mann EWAS effect also increased as

Insight 1. EWAS effect sizes increase over time for all child health outcomes

<u>lnsight 1. EWAS</u>
Our first key findir
time: i.e. the $\frac{1}{2}$ Our first key finding is that across *all* five outcomes, mean EWAS effect sizes increased over
time; i.e., they were stronger in the cross-sectional childhood analyses as compared to the
prospective birth analyses. This m proximity of the cross-sectional EWASs may better reflect immediate causal effects of proximity of the cross-sectional EWASs may better reflect immediate causal effects o
DNAm on an outcome; (ii) in addition to genetic and prenatal environmental factors
captured by DNAm at birth, DNAm in childhood may also proximity of the cross-sectional European process and prenatal environmental factors
captured by DNAm at birth, DNAm in childhood may also reflect the accumulation of
relevant postnatal environmental exposures and genetic captured by DNAm at birth, DNAm in childhood may also reflect the accumulation of
relevant postnatal environmental exposures and genetic effects¹¹; (iii) peripheral blo
childhood) may be a more informative tissue than c relevant postnatal environmental exposures and genetic effects¹¹; (iii) peripheral bloc
childhood) may be a more informative tissue than cord blood (at birth), e.g. due to tis
differences in cell-type composition or immu childhood) may be a more informative tissue than cord blood (at birth), e.g. due to tissue
differences in cell-type composition or immune profile — although we do not find evidence
of enrichment for blood tissue-specific p differences in cell-type composition or immune profile - although we do not find evidence of enrichment for blood tissue-specific pathways in health-relevant CpGs that changed ove
time; and (iv) there may be unmeasured confounding (e.g., lifestyle, allergens) and reverse
causation in childhood, which is more li time; and (iv) there may be unmeasured confounding (e.g., lifestyle, allergens) and reverse
causation in childhood, which is more likely to affect cross-sectional analyses than
prospective analyses.¹⁹ Indeed, Mendelian causation in childhood, which is more likely to affect cross-sectional analyses than
prospective analyses.¹⁹ Indeed, Mendelian randomization studies suggest that for at least
some sites, DNAm levels are a consequence, ra prospective analyses.¹⁹ Indeed, Mendelian randomization studies suggest that for a
some sites, DNAm levels are a consequence, rather than a cause, of BMI^{20,21} or ast
While we can only speculate as to the most likely re some sites, DNAm levels are a consequence, rather than a cause, of BMI^{20,21} or asthma²².
While we can only speculate as to the most likely reason for the observed effect size
increase, we can conclude that it is consis While we can only speculate as to the most likely reason for the observed effect size increase, we can conclude that it is consistent for different outcomes, and to a comparable increase, we can conclude that it is consistent for different formulations of different different formulations.
Insight 2. Higher effect sizes ≠ more significant findings
While EWAS effect sizes rebuth: increased, this di

m signt 2. Higher effect sizes τ more significant findings

degree.
Insight 2. Higher effect sizes \neq more significant find
While EWAS effect sizes robustly increased, this did no $\begin{array}{c} \n\frac{1}{2} & \frac{1}{2} \\ \n\frac{1}{2} & \frac{1}{$ While EWAS effect sizes robustly increased, this did not necessarily result in more significant findings, as the signal also became 'noisier' with larger SE in childhood analyses. For BMI, the increase in effect sizes did findings, as the signal also became 'noisier' manifolger search statistical significance;
the increase in effect sizes did correspond with an increase in statistical significance;
actually decreased from birth to childhood however, for the other four outcomes significance on average either remained the sa
actually decreased from birth to childhood, as evidenced most clearly for ADHD. Moc
specification is unlikely to explain differences in er actually decreased from birth to childhood, as evidenced most clearly for ADHD. Model
specification is unlikely to explain differences in error, as outcome definitions and covariate
were largely the same between the prospe actually decreased from the from birth to childhood, as evidenced most clearly for ADHD. As pecification is unlikely to explain differences in error, as outcome definitions and covar
were largely the same between the prosp specification is unlikely to emploid interferences in error, as outcome definition and correlations with the were largely the same between the prospective and cross-sectional EWAS analyses; with the 11 were largely the same between the prospective and cross-sectional EWAS and cross-sectional ± 11

proportion estimates (using different age- and tissue-appropriate reference panels).
Three other plausible 'culprits' for the noisier signal include sample size differer
between-study heterogeneity, and increasing DNAm var Three other plausible 'culprits' for the noisier signal include sample size differ
between-study heterogeneity, and increasing DNAm variance with age. First, an imba
in sample sizes (and associated power) between the birth Three curve processing to the noising DNAm variance with age. First, an imbalance
le sizes (and associated power) between the birth and childhood EWASs could have
ifferences in mean statistical significance. However, resul between study heterogeneity, and we stating 2 chain variables in age. They, an infraeduce
in sample sizes (and associated power) between the birth and childhood EWASs could have
led to differences in mean statistical signi in sampled to differences in mean statistical significance. However, results remained largely
consistent when re-running analyses restricting sample sizes to be equal between time
points, ruling out this explanation. Secon consistent when re-running analyses restricting sample sizes to be equal between tir
points, ruling out this explanation. Second, we found that for all outcomes except GF
between-study heterogeneity (i.e. systematic variab points, ruling out this explanation. Second, we found that for all outcomes except GPF,
between-study heterogeneity (i.e. systematic variability in effect sizes across the
contributing cohorts) increased when DNAm was meas points, ruling out this explanation. The contributive in the cases the
between-study heterogeneity (i.e. systematic variability in effect sizes across the
contributing cohorts) increased when DNAm was measured in childhood contributing cohorts) increased when DNAm was measured in childhood, potenti
to more statistical uncertainty. Contributing factors may include (i) differences in
assessment age, which varied substantially less in EWAS ana to more statistical uncertainty. Contributing factors may include (i) differences in DNAm
assessment age, which varied substantially less in EWAS analyses at birth (cohort
differences in the order of days) compared to EWAS to more statistical uncertainty. Contributing more can provide (i) and statistical uncertainty assessment age, which varied substantially less in EWAS analyses at birth (cohort differences in the order of days) compared to differences in the order of days) compared to EWAS in childhood (with age rangin
to 17 years for asthma); and (ii) environmental differences between the included
which may cumulatively affect DNAm patterns (e.g., dietary f to 17 years for asthma); and (ii) environmental differences between the included cohorts,
which may cumulatively affect DNAm patterns (e.g., dietary factors, pollutant exposure,
etc.), leading to more context-dependent ass which may cumulatively affect DNAm patterns (e.g., dietary factors, pollutant exposure,
etc.), leading to more context-dependent associations in childhood. Importantly, howev-
between-study heterogeneity does not seem to f etc.), leading to more context-dependent associations in childhood. Importantly, however, between-study heterogeneity does not seem to fully account for increasing error in EWAS estimates over time. Indeed, when we re-ran meta-regression analyses only in ALSPAC, we found largely the same pattern of findings as estimates over time. Indeed, when we re-ran meta-regression analyses only in ALSPAC, we
found largely the same pattern of findings as the overall meta-analyses, meaning that
sources of variability related to the use of mul sources of variability related to the use of multiple cohorts are unlikely to fully explain the

fources of variability related to the use of multiple cohorts are unlikely to fully explain
observed temporal differences in EWAS signal.
A third explanation relates to DNAm variance. Variance for most DNAm sites
increases sources of temporal differences in EWAS signal.
A third explanation relates to DNAm variance. Variance for most DNAm sites
increases with age (on average increasing 1.26 fold per year from birth), with only a minori
of DNA A third explanation relates to DNAm var
increases with age (on average increasing 1.26
of DNAm sites showing significant decreases in
variance reflects in part variation relevant to th A third expansion relative to Definite the Lindsen Character in the DNA is a set with age (on average increasing 1.26 fold per year from birth), with only a im sites showing significant decreases in variance.²³ It is lik of DNAm sites showing significant decreases in variance.²³ It is likely that this increased
variance reflects in part variation relevant to the studied health outcomes, e.g. reflectin_i
additional important postnatal ex variance reflects in part variation relevant to the studied health outcomes, e.g. reflecting
additional important postnatal exposures, which results in increased effect sizes. At the
same time, the increased variance likel variance reflects in part variation reflects in the studied increased effect sizes. At the
same time, the increased variance likely also includes a substantial amount of variance
unrelated to the studied health-related out same time, the increased variance likely also includes a substantial amount of variance
unrelated to the studied health-related outcomes, increasing the standard error (i.e. add
noise) of the DNAm estimates and lowering po

unrelated to the studied health-related outcomes, increasing the standard error (i.e. ad
noise) of the DNAm estimates and lowering power.
In summary, our findings caution against the assumption that larger effect sizes
EWA noise) of the DNAm estimates and lowering power.
In summary, our findings caution against the assumption that larger effect sizes in
EWAS lead to the identification of more hits. Rather, they suggest that statistical power In summary, our findings caution against the
EWAS lead to the identification of more hits. Rather
varies depending on factors such as the degree of ure
timing of DNAm assessment, and the potentially cau In summary, our finalings caution against the assumption that larger since sizes in
lead to the identification of more hits. Rather, they suggest that statistical power
lepending on factors such as the degree of uncertaint Varies depending on factors such as the degree of uncertainty and study heterogeneity,
timing of DNAm assessment, and the potentially causal nature and direction of associati
between DNAm and a given outcome. varining of DNAm assessment, and the potentially causal nature and direction of associations
between DNAm and a given outcome.
Insight 3. Epigenetic signals associated with child outcomes are time-specific and

timing of DNAm assessment, and the potentially causal nature and direction of assessment
between DNAm and a given outcome.
Insight 3. Epigenetic signals associated with child outcomes are time-specific and
pleiotropic between the anti-age in caternal.
Insight 3. Epigenetic signals associat
pleiotropic $\frac{1}{5}$ Insight 3. Epigenetic signals associated with child outcomes are time-specific and pleiotropic

association signals at birth versus in childhood: generally, for a given outcome, estimated birth did not correlate with those in childhood – or only modestly in the case of ADHI
birth did not correlate with those in child birth did not correlate with those in childhood $-$ or only modestly in the case of ADHD.
12 birth did not correlate with those in childhood – or only modestly in the case of ADHD.

Based on the available and comparable data of the life stages, or whether DNAm associations become
more stable and comparable after some developmental point.^{10,23} These temporal
differences raise the question of which DN signals extends more stable and comparable after some developmental point.^{10,23} These temporal
differences raise the question of which DNAm assessment time point may be most relevar
for health. For biomarker purposes, ou more stable and comparable after some developmental point.^{20,23} These temporal
differences raise the question of which DNAm assessment time point may be most
for health. For biomarker purposes, our results suggest that D for health. For biomarker purposes, our results suggest that DNAm estimates from cross-
sectional childhood analyses may explain higher phenotypic variance, but at the cost of
higher uncertainty of estimates. This may lead phenotype, and thus less useful for prediction of later outcomes.²⁴ Our results caution that MPS developed from one DNAm time point may generalize poorly to different time-points.
As such, repeated assessments of DNAm an higher uncertainty of estimates. This may lead to noisier methylation profile scores (MP
akin to polygenic scores or PGS), which are also more likely to reflect consequences of a
phenotype, and thus less useful for predict akin to polygenic scores or PGS), which are also more likely to reflect consequences of a
phenotype, and thus less useful for prediction of later outcomes.²⁴ Our results caution tha
MPS developed from one DNAm time point phenotype, and thus less useful for prediction of later outcomes.²⁴ Our results caution the MPS developed from one DNAm time point may generalize poorly to different time-poin As such, repeated assessments of DNAm and th As such, repeated assessments of DNAm and the combination of multiple age-specific
scores may be needed to improve MPS performance, although specific guidelines are
difficult to formulate based on the present findings. For Scores may be needed to improve MPS performance, although specific guidelines are
difficult to formulate based on the present findings. For instance, MRSs based on allerg
related EWAS performed similarly well when tested a difficult to formulate based on the present findings. For instance, MRSs based on aller
related EWAS performed similarly well when tested at both age 6 and 10 years,²⁵ but
differences between birth and childhood methylat

DNAm associations with ADHD, GPF and asthma are to some degree shared. This is in line related EWAS performed similarly well when tested at both age 6 and 10 years,²⁵ but
differences between birth and childhood methylation profiles are likely more impactf
Surprisingly, the consistency of estimates across s Surprisingly, the consistency of estimates across some child outcomes was larger
than between time points for the same outcome. Our correlation analyses suggest that
DNAm associations with ADHD, GPF and asthma are to some Surprisingly, the consistency of estimates an external entertainmental outget
tween time points for the same outcome. Our correlation analyses suggest that
associations with ADHD, GPF and asthma are to some degree shared. DNAm associations with ADHD, GPF and asthma are to some degree shared. This is in line with previous studies pointing to phenotypic and genetic correlations between these outcomes^{26–29}, and may point towards an early sh with previous studies pointing to phenotypic and genetic correlations between these
outcomes^{26–29}, and may point towards an early shared origin of these conditions reflected
the methylome or network effects among the phe outcomes^{26–29}, and may point towards an early shared origin of these conditions refle
the methylome or network effects among the phenotypes. Enrichment analyses sugge
that neural pathways may be involved in all tested h the methylome or network effects among the phenotypes. Enrichment analyses suggest
that neural pathways may be involved in all tested health outcomes (particularly mental
phenotypes) and may partly explain the observed cor phenotypes) and may partly explain the observed correlation. On the other hand, the phenotypes) and may partly explain the observed correlation. On the other hand, the
observed negative correlation between (birth/childhood) ADHD and (childhood) BMI
estimates is more perplexing. Children with ADHD are more phenotypes) and may partly explain the observed negative correlation between (birth/childhood) ADHD and (childhood) BMI
estimates is more perplexing. Children with ADHD are more likely to be overweight an
versa,^{30,31} and estimates is more perplexing. Children with ADHD are more likely to be overweight and versa, $30,31$ and BMI and ADHD also show positive genetic correlations. $27,32$ This may inthat epigenetic risk mechanisms for ADHD are estimate in the represents is more in the more in the removement of the setser, 27,32 This may indicate that epigenetic risk mechanisms for ADHD are associated with lower BMI in childhood, but are overshadowed by (nonthat epigenetic risk mechanisms for ADHD are associated with lower BMI in childhood, but
are overshadowed by (non-methylation related) mechanisms causing positive phenotypic
correlations. are overshadowed by (non-methylation related) mechanisms causing positive phenotypic

Study limitations

Our meta-regression approach enabled us to quantify longitudinal trends (changes in EWAS
effect sizes, standard error and statistical significance) in the relationship between DNAm Study limita
Our meta-reg
effect sizes, s sice design The interarring constrainable in the responsive approach in the relationship between DNAm
assessed at multiple time points (birth, childhood) and various child health outcomes, as
well as to estimate how EWAS signals corre effects assessed at multiple time points (birth, childhood) and various child health outcomes, as
well as to estimate how EWAS signals correlate over time and across outcomes. However,
summary statistics-based approaches a well as to estimate how EWAS signals correlate over time and across outcomes. However
summary statistics-based approaches also have several limitations. While we accounted f
repeated measures from the same cohorts, the deg we have to estimate how EUNAS signals correlated throughout intuitions. While we accounted forepeated measures from the same cohorts, the degree of sample overlap across time point and outcomes could not be explicitly mode repeated measures from the same cohorts, the degree of sample overlap across time points
and outcomes could not be explicitly modeled based on summary data.³³ That said,
sensitivity analyses in a single cohort with large and outcomes could not be explicitly modeled based on summary data.³³ That said,
sensitivity analyses in a single cohort with largely overlapping samples did not alter
conclusions. In addition, modeling effect size chang and outcomes could not be explicitly modeled based on summary data.³³ That said,
sensitivity analyses in a single cohort with largely overlapping samples did not alter
conclusions. In addition, modeling effect size chang sensitivity analyses in a single controlled inappendent largely overl_{pping} complex and not alternative
conclusions. In addition, modeling effect size changes and between-study heteroger
more granularly to incorporate inf more granularly to incorporate information on specific age of DNAm assessment (i.e.
13 more granularly to incorporate information on specific age of DNA materials (i.e., \sim

Individual characteristic we cannot model with the given data is sex. It is possible that
associations may differ depending on sex and affect childhood DNAm associations
disproportionately, especially after puberty. Future individual characteristic we cannot model with the given data to cannot associations
disproportionately, especially after puberty. Future studies with individual-level data s
also study the impact of increasing DNAm varian disproportionately, especially after puberty. Future studies with individual-level da
also study the impact of increasing DNAm variance on association estimates. Lastly
could not perform formal epigenetic correlation tests disproportionately, especially after puberty. Future studies with individual-level data, and the
could not perform formal epigenetic correlation tests on individual-level data, and the
correlation analyses of regression co could not perform formal epigenetic correlation tests on individual-level data, and the
correlation analyses of regression coefficients should therefore be interpreted as
hypothesis-generating for future research.
With cur

correlation analyses of regression coefficients should therefore be interpreted as
hypothesis-generating for future research.
With current study designs, it is also impossible to disentangle timing difference
from tissue d hypothesis-generating for future research.
With current study designs, it is also impossible to disentangle timing differences
from tissue differences between cord and peripheral blood. Each EWAS adjusted for
estimated cel With current study designs, it is also
from tissue differences between cord and p
estimated cell proportions, but such correc
within time points and tissues, but not acro Sue differences between cord and peripheral blood. Each EWAS adjusted for
ed cell proportions, but such corrections only adjust for cell composition difference
ime points and tissues, but not across tissues²⁶. Morphogene estimated cell proportions, but such corrections only adjust for cell composition differentian within time points and tissues, but not across tissues²⁶. Morphogenesis pathways show evidence of enrichment in case of BMI a within time points and tissues, but not across tissues²⁶. Morphogenesis pathways showed
some evidence of enrichment in case of BMI and asthma, leaving the possibility open for an
involvement of tissue differentiation. Fu some evidence of enrichment in case of BMI and asthma, leaving the possibility open for an
involvement of tissue differentiation. Future studies are needed that examine different
tissues at birth (to determine the specific tissues at birth (to determine the specificity of the findings to cord blood as opposed to the
neonatal period in general) as well as DNAm at multiple time points in childhood (to test if
effect sizes change non-linearly a tissues at birth (to determine the specificity of the findings to cord blood as opposed to
neonatal period in general) as well as DNAm at multiple time points in childhood (to tes
effect sizes change non-linearly across de the finding (the determine the specific) of the findings to cord blood to the finding present in the specific to determine the effect sizes change non-linearly across developmental periods).¹⁰ While our analyses provided neonatal period in general) as well as DNAM at DNAM at DNAM priods).¹⁰ While our analyses
provided important new insights into genome-wide trends, they were mostly underpowere
to identify *specific* DNAm sites showing lo effect sizes change non-linearly across developmental periods).⁴⁰ While our analyses
provided important new insights into genome-wide trends, they were mostly underp
to identify *specific* DNAm sites showing longitudinal providentify *specific* DNAm sites showing longitudinal changes in associations at a genome-wide level of significance; as such, larger studies are needed to reliably characterize epigenetic changes in associations for ind to identify specific DNAm sites showing longitudinal changes in associations at a genome-
wide level of significance; as such, larger studies are needed to reliably characterize
epigenetic changes in associations for indiv where the studies in associations for individual sites. Finally, expanding analyses to outcomes should be pursued in future research.
Conclusions epigenetic changes in associations in associations should be pursued in future research.
Conclusions
Overall, our results suggest developmentally-specific associations between DNAm and child

outcomes should be pursued in future research.
Conclusions
Overall, our results suggest developmentally-spe
health outcomes, when assessing DNAm at birth C
C
I Conclusions
Overall, our re
health outcor
results from c
childhood cor health outcomes, when assessing DNAm at birth vs childhood. This implies that EWAS
results from one time point are unlikely to generalize to another (at least based on birth vs
childhood comparisons): a consequential findi health stream and the point are unlikely to generalize to another (at least based on birth childhood comparisons): a consequential finding, given that most research to date exa
DNAm at a single assessment time-point. Longi result from one time point are unlikely to generally to antenna (at least based on birth are childhood comparisons): a consequential finding, given that most research to date examine
DNAm at a single assessment time-point. DNAm at a single assessment time-point. Longitudinal studies with repeated epigenetic
assessments are direly needed to shed light on the dynamic relationship between DNAm,
development and health, as well as to enable the c assessments are direly needed to shed light on the dynamic relationship between DNAm
development and health, as well as to enable the creation of more reliable and
generalizable epigenetic biomarkers. More broadly, this st development and health, as well as to enable the creation of more reliable and
generalizable epigenetic biomarkers. More broadly, this study underscores the importance
of considering the time-varying nature of DNAm in epig generalizable epigenetic biomarkers. More broadly, this study underscores the i
of considering the time-varying nature of DNAm in epigenetic research and sup_l
potential existence of epigenetic 'timing effects' on child h generalizable epigenetic biomarkers. More broadly, this study understand in importance
of considering the time-varying nature of DNAm in epigenetic research and supports the
potential existence of epigenetic 'timing effect potential existence of epigenetic 'timing effects' on child health.

The time-variable support of PNAM in each and support of DNAM in the support of the support of the support of potential existence of epigenetic 'timing effects' on child health.

Methods
_{Data}

We requested cohort-level epigenome-wide summary statistics from five meta-analytic studies previously performed by the PACE Consortium. We obtained permission for re-
analysis from the meta-analysis leads and representatives of all originally participating
cohorts, except for the GOYA study, which was ex cohorts, except for the GOYA study, which was excluded here from further analysis. The

EWAS summary statistics included the association between DNAm (predictor) and a phenotype (outcome). DNAm was either measured in cord blood at birth or in peripheral previously approved the included studies.^{7–9,17,18}
EWAS summary statistics included the association between DNAm (predictor) a
phenotype (outcome). DNAm was either measured in cord blood at birth or in peripher
blood in previously approved the included studies.^{7–9,17,18}
EWAS summary statistics included the as
phenotype (outcome). DNAm was either measure
blood in childhood with either Illumina 450K or E
remained after QC, see below). Pre Summary statistic included the association of blood at birth or in peripheral
a childhood with either Illumina 450K or EPIC arrays (although only 450K DNAm sites
ad after QC, see below). Predictors were the DNAm betas rang phenotype (contently entitled in content in the entitled in cord birth or in peripheral
blood in childhood with either Illumina 450K or EPIC arrays (although only 450K DNAm sit
remained after QC, see below). Predictors wer remained after QC, see below). Predictors were the DNAm betas ranging from 0 to 1,
corresponding to 0 to 100 percent methylation, with analyses for GPF and Sleep having
trimmed DNAm outliers outside the range of $[25^{th}$ corresponding to 0 to 100 percent methylation, with analyses for GPF and Sleep havir
trimmed DNAm outliers outside the range of $[25^{th}$ percentile - (3*interquartile range (
to 75th percentile + 3*IQR). ADHD, GPF and s trimmed DNAm outliers outside the range of [25th percentile - (3*interquartile range (IQR)
to 75th percentile + 3*IQR). ADHD, GPF and sleep were assessed via parental questionnaires
and BMI was computed based on measur to 75th percentile + 3*IQR). ADHD, GPF and sleep were assessed via parental questionnaires to 75" percentile + 3*IQR). ADHD, GPF and sleep were assessed via parental questionnaires
and BMI was computed based on measured height and weight. ADHD, GPF and sleep were
assessed via parental questionnaires and BMI was assessed via parental questionnaires and BMI was computed based on measured height and
weight. These were modelled as continuous measures that were z-score standardized within
each cohort.^{8,9,17,18} Asthma was classified assessed via parameter and BMI was sent that the sentence of the deal of the weight. These were modelled as continuous measures that were z-score standardized within each cohort.^{8,9,17,18} Asthma was classified based on d each cohort.^{8,9,17,18} Asthma was classified based on doctor's diagnosis and symptoms in past
years, and analyzed in a dichotomous fashion.⁷ All EWAS were adjusted for sex, maternal
age, maternal education, maternal smo years, and analyzed in a dichotomous fashion.⁷ All EWAS were adjusted for sex, maternal
age, maternal education, maternal smoking, cell proportions and possible batch effects, in
addition to other variables, which differ years, and analyzed in a dichotomous fashion.' All EWAS were adjusted for sex, maternal
age, maternal education, maternal smoking, cell proportions and possible batch effects, in
addition to other variables, which differed addition to other variables, which differed depending on outcome and time-point. A variety
of analysis models were employed, such as OLS linear models (ADHD, sleep), robust linear
models (GPF, BMI) and logistic regression of analysis models were employed, such as OLS linear models (ADHD, sleep), robust linear
models (GPF, BMI) and logistic regression (asthma). For ADHD, some cohorts applied linear
mixed models, when repeated measures of ADH

models (GPF, BMI) and logistic regression (asthma). For ADHD, some cohorts applied linear
mixed models, when repeated measures of ADHD were available (Table 1).
We applied the following additional quality control: 1. Kept mixed models, when repeated measures of ADHD were available (Table 1).
We applied the following additional quality control: 1. Kept only autosomal DNAm
sites, 2. removed DNAm sites with information in less than three cohor sites, 2. removed DNAm sites with information in less than three cohorts or 1000
participants per time-point, 3. kept only CpG sites present both at birth and in ch
removed cross-reactive probes using the maxprobe 0.0.2 pa removed DNAm sites with information in less than three cohorts or 1000
ants per time-point, 3. kept only CpG sites present both at birth and in childhood, and
cross-reactive probes using the maxprobe 0.0.2 package
/github. participants per time-point, 3. kept only CpG sites present both at birth and in chi
removed cross-reactive probes using the maxprobe 0.0.2 package
(https://github.com/markgene/maxprobes). Finally, to examine whether the d participants per time-point of the maxprobe 0.0.2 package

(https://github.com/markgene/maxprobes). Finally, to examine whether the differences in

statistical significance were influenced by sample size differences, we al removed cross-reactive probes analytical cross-package.
(https://github.com/markgene/maxprobes). Finally, to examine wild
statistical significance were influenced by sample size differences,
sensitivity analyses with simil (and the distinct of the distinct of the distinction statistical significance were influenced by sample size differences, we also performed
sensitivity analyses with similar sample sizes at both time points. We removed (co sensitivity analyses with similar sample sizes at both time points. We removed (combi
of) cohorts which resulted in the most similar sample sizes between cohorts (Table S1
Statistical Analysis sensitivity analyses minimum sample sizes at a complete points. It sensitivity (Table S1).
Of) cohorts which resulted in the most similar sample sizes between cohorts (Table S1).
Statistical Analysis
Each summary statisti

- .
Statistical Analysis
Each summary statistic contained information on the regression coefficient (β_{jk}) and
standard error. β represents the expected difference in the outcome in SD between no a Statistical Analysis
Each summary statistic contained information on the regression coefficient (β_{ik}) and Each summary statistic contained information on the regression coefficient of p_{jk}y and
standard error. β represents the expected difference in the outcome in SD between i
full methylation at the tested CpG site at DNAm full methylation at the tested CpG site at DNAm assessment time-point j (birth or childhood)
estimated in cohort k. We applied multi-level meta-regressions to pool effect sizes across full methylatic at the tested c_pC site at DNAM assessment and point of the test at a set at a set at the set of site at a set of site at the set of sites at the set of sites at the set of sites and to model changes in ef cohorts and to model changes in effect sizes depending on DNAm assessment time-point.
15 cohorts and to model changes in effect sizes depending on DNAm assessment time-point.

Repeated measures from cohorts that contributed association estimates for both DNAm at
birth and in childhood were taken into account with a random intercept. The main model
therefore took the form of:
 $\beta_{ik} = \beta_{birth} + \beta_{\Delta child$ birth and in childhood with a random into account with a random intercept. The main models
 $\beta_{jk} = \beta_{birth} + \beta_{\Delta childhood} + u_k + r_k$

 $\beta_{jk} = \beta_{birth} + \beta_{\Delta childhood} + u_k + r_k$
 β_{birth} is the intercept and rep |
|
| $β_{\text{birth}}$ is the intercept and
methylation at a CpG site
 $β_{\text{Achildhood}}$ refers to the ch Both is the intercept and represents the position and all program discussion $\beta_{\Delta childhood}$, respectively.
 $\beta_{\Delta childhood}$ refers to the change in association from DNAm at birth to childhood.
 u_k is the study random effect a $\beta_{\Delta childhood}$ refers to the change in association from DNAm at birth to childhood
 u_k is the study random effect and refers to deviation of the mean association
k from overall mean associations.
 r_k denotes residual error u_k is the study random effect and refers to deviation of the mean associations within cohort
k from overall mean associations.
r_k denotes residual error

We also ran a statistically identical model with reverse time direction to extract DNAm r_k denotes residual error
We also ran a statistically identical
effects at childhood. We applied the residual error
We also ran a statistically
effects at childhood. We
separately using metafor \
}
} effects at childhood. We applied these meta-regression models to each DNAm site
separately using metafor 4.2.0³⁴ in R 4.2.2³⁵. After estimating the associations and their
change for each CpG site, we aggregated statis effects at childhood. Separately using metafor 4.2.0³⁴ in R 4.2.2³⁵. After estimating the associations and the change for each CpG site, we aggregated statistics across the genome to characterit trends. Specifically, separately using metafor 4.2.0³⁴ in R 4.2.2³³. After estimating the associations and their
change for each CpG site, we aggregated statistics across the genome to characterize glo
trends. Specifically, we examined acr trends. Specifically, we examined across all CpG sites the mean absolute effect size at birth

(| $\overline{\beta}_{\text{birth}}$ |), mean absolute effect size in childhood (| $\overline{\beta}_{\text{childhood}}$ |), and the mean effect size

difference between b ($|\overline{\beta}_{\text{birth}}|$), mean absolute effect size in childhood ($|\overline{\beta}_{\text{childhood}}|$), and the mean effect size
difference between birth and childhood ($|\Delta \overline{\beta}_{\text{Achildhood}}|$). In addition, we examined trends of
statistical significance statistical significance by taking the mean z test statistic of $\beta_{\text{birth}}(| \ z_{\text{birth}}|)$ and β_{children}

(| $\overline{z}_{\text{children}}$), representing the evidence of association for DNAm at birth and childhood,

respectively. Furthermore (| z_{childhood}|), representing the evidence of association for DNAm at birth and childhood,
respectively. Furthermore, we also characterized the change in mean statistical significan
from birth to childhood methylation (

From birth to childhood methylation ($|Δz|$).
We also examined whether between-study heterogeneity changed between birth
and childhood estimates by adding a random slope of $β_{\Delta childhood}$ on the cohort level. We
extracted τ, Idhood estimates by adding a random slope of $\beta_{\Delta childhood}$ on the cohort level. We
ed τ , which indicates to which degree DNAm effects vary due to between-study
geneity within 1SD. In other words, assuming no sampling err extracted τ, which indicates to which degree DNAm effects vary due to between-study heterogeneity within 1SD. In other words, assuming no sampling error and normal
distribution, 67% of estimates are expected to be within β +-τ due to study differen
Reported correlations are spearman correlations. GO te distribution, 67% of estimates are expected to be within β +-t due to study differences. Reported correlations are spearman correlations. GO term enrichment for DNAm sites with nominally significant change and nominally significant association for at least one time point $mmin$, significant change and normally significant association for at least one time point
was tested using missMethyl $1.36.0$.^{36,37} was tested using missMethyl 1.36.0.^{30,37}
Marshall
All Constants and the solid formulation of the solid formulation of the solid formulation of the solid formula
Solid formulation of the solid formulation of the solid for

Data-AVailability
Original analysis code and example data can be found at https://github.com/aneumann-

Acknowledgments
Wadankali analysis code at https://github.com/aneumann-aneumann-

science, epigenetic_e anal<u>ogenetic timinated analysis summary statistics can be dominant at a
https://doi.org/10.5281/zenodo.10720466 (Will be made public after acceptance).
Acknowledgments
we thank all the children and </u> $\frac{1}{1}$ the support of hospitals, midwives, and pharmacies. We also gratefully acknowledge all
researchers who contributed to the original PACE meta-analyses included in this study.
The work of AN and CAMC was supported by the Eur

The support of hospitals, middle of the supported by the support of hospitals, middled in this study.
The work of AN and CAMC was supported by the European Research Council (TEMPO; gratement No 101039672) and the European The work of AN and CAMC was supported by the European Research Council (TEMPO; grant
agreement No 101039672) and the European Union's HorizonEurope Research and
Innovation Programme (FAMILY, grant agreement No 101057529). $\begin{array}{c} \n\overline{1} \\
\overline{1} \\
\overline{1} \\
\overline{1}\n\end{array}$ The work of AN and CAMC was supported by the European Union's HorizonEurope Research and
Innovation Programme (FAMILY, grant agreement No 101057529). The work of CAMC is
further supported by the European Union's Horizon 20 Innovation Programme (FAMILY, grant agreement No 101057529). The work of CAMC is
further supported by the European Union's Horizon 2020 Research and Innovation
Programme (EarlyCause, grant agreement No 848158; HappyMums, g Further supported by the European Union's Horizon 2020 Research and Innovation
Programme (EarlyCause, grant agreement No 848158; HappyMums, grant agreement No
101057390). CAMC and JFF are supported by the European Union's Programme (EarlyCause, grant agreement No 848158; HappyMums, grant agreeme
101057390). CAMC and JFF are supported by the European Union's Horizon Europe
Programme (STAGE project, grant agreement no.101137146). This researc Programme (Early Cause) grant agreement to the European Union's Horizon Europe
Programme (STAGE project, grant agreement no.101137146). This research was conducte
while CAMC was a Hevolution/AFAR New Investigator Awardee i Programme (STAGE project, grant agreement no.101137146). This research was con
while CAMC was a Hevolution/AFAR New Investigator Awardee in Aging Biology and
Geroscience Research.
LST was supported by the CAPICE (Childhood

While CAMC was a Hevolution/AFAR New Investigator Awardee in Aging Biology and
Geroscience Research.
LST was supported by the CAPICE (Childhood and Adolescence Psychopathology: unravelling
the complex etiology by a large I Geroscience Research.
LST was supported by the CAPICE (Childhood and Adolescence Psychopathology: unr
the complex etiology by a large Interdisciplinary Collaboration in Europe) project, the
European Union's Horizon 2020 re LST was supported by t
the complex etiology by
European Union's Horiz
Curie Actions – MSCA-li LAT WAS Supported by the CAPICE (Childhood and Adolescence Psychopathology) and Assumption
the complex etiology by a large Interdisciplinary Collaboration in Europe) project, the
European Union's Horizon 2020 research and European Union's Horizon 2020 research and innovation programme, Marie Sklodows
Curie Actions – MSCA-ITN-2016 – Innovative Training Networks under grant agreemer
number 721567.
SJL was supported in part by the Intramural R Eurie Actions – MSCA-ITN-2016 – Innovative Training Networks under grant agreement
number 721567.
SJL was supported in part by the Intramural Research Program of the NIH, NIEHS Z01
ES49019.

Currential Model in the state of the University of the Mathias Actions – Innovative Innovative Innovative Inno
Curies – SIL was supported in part by the Intramural Research Program of the NIH, NIEHS 201
ES49019.
SEH and CM number 721567.
SJL was supported in part by the Intramural Research Program of the NIH, NIEHS 201
ES49019.
SEH and CMP was partly supported by The Norwegian Research council no 262700 ar
Norwegian Cancer Society project no

ES49019.
SEH and CMP was partly supported by The Norwegian Research council no 262700 an
Norwegian Cancer Society project no 244291. SEH and C
Norwegia
See suppl

See supplementary information for cohort-specific acknowledgments and funding.

Norwegian Cancer Society projective 2442291.
See supplementary information for cohort-spe
Support for title page creation and format was $\frac{1}{2}$ Support for title page creation and format was provided by AuthorArranger, a tool
developed at the National Cancer Institute. $\frac{1}{2}$ Support for the National Cancer Institute.
Support for the National Cancer Institute.
Author Contributions

Author contributions

Author contributions
AN and CC developed the study design and $\frac{1}{2}$ analysis. CC supervised the study. All co-authors contributed to the original epigenome-wide association studies used in the meta-regression and revised the manuscript critically.
 17 association studies used in the meta-regression and revised the manuscript critically.

Competing interests
The authors declare that they have no conflict of interest.

Materials and Correspondence

The authors density and they have no connect conflict that the
Materials and Correspondence
For correspondence and material requests, please contact
(a.neumann@erasmusmc.nl). $\begin{array}{c} \n \text{I} \\
 \$

Tables

For correspondence and material requests, please contact Alexander Alexander
(a.neumann@erasmusmc.nl).
Table 1 Published epigenome-wide association studies of child developme
from PACE, jointly re-analyzed in present study (an emanage commonship).
Tables
Table 1 Published epigenom
from PACE, jointly re-analyzi
Table 2 Association between

Table 1 Published epigenome-wide association studies of child developmental outcomes
from PACE, jointly re-analyzed in present study
Table 2 Association between DNA methylation either at birth or in childhood and child
dev

Table 2 Association between DNA methylation
developmental outcomes (full sample)
Table 3 Comparison of birth EWAS (i.e. prospec
cross-sectional analysis): Overview of study find Table 2 Association between DNA methylation either at birth or in childhood and child
developmental outcomes (full sample)
Table 3 Comparison of birth EWAS (i.e. prospective analysis) versus childhood EWAS (i.
cross-sectio Table 3 Comparison of birth EWAS (i.e.
Cross-sectional analysis): Overview of s
Table 4 Gene ontology enrichment ana
sites showing change from birth to chile

Table 3 Comparison of birth EWAS (i.e. prospective analysis) versus childhood EWAS (i.e.
cross-sectional analysis): Overview of study findings
Table 4 Gene ontology enrichment analyses: top 10 terms for phenotype-associate Table 4 Gene ontology enrichment analyses: top 10
sites showing change from birth to childhood
Table S1 Cohort sample sizes
Table S2 Cohort overlap

Table 4 Gene ontology emicimient analyses: top 10 terms for phenotype-associated DNAm
sites showing change from birth to childhood
Table S1 Cohort sample sizes
Table S2 Cohort overlap
Table S3 Effect directions sites showing change from birth to children
Table S1 Cohort sample sizes
Table S3 Effect directions
Table S4 Equal a consitivity analysis Table S1 Cohort sample sizes
Table S2 Cohort overlap
Table S4 Equal n sensitivity ar
Table S5 ALSBAC consitivity ar Table S2 Cohort overlap
Table S3 Effect directions
Table S4 Equal n sensitivit
Table S5 ALSPAC sensitivi
Table S6 Heterogeneity Table S3 Effect directions
Table S4 Equal n sensitivit
Table S6 Heterogeneity
Table S3 Ensishment ADUI Table S5 ALSPAC sensitivity analysis
Table S6 Heterogeneity
Table S7 Enrichment ADHD
Table S8 Enrichment GPF Table S5 ALSPAC sensitivity analysis
Table S6 Heterogeneity
Table S8 Enrichment ADHD
Table S8 Enrichment GPF Table S7 Enrichment ADHD
Table S8 Enrichment GPF
Table S9 Enrichment Sleep
Table S10 Enrichment BMI Table S7 Emichment ADHD
Table S8 Enrichment GPF
Table S10 Enrichment BMI
Table S11 Enrichment Ashb Table S8 Emeriment GFT
Table S9 Enrichment Slee
Table S10 Enrichment BM
Table S11 Enrichment Ast Table S3 Emement Sleep
Table S10 Enrichment BMI
Table S11 Enrichment Asth
Figure legends Table S10 Enrichment BMI
Table S11 Enrichment Asth
Figure 1. Mean effect sizes

Figure legends

Table S11 Enrichment Asthma
Figure 1. Mean effect sizes and
Mean effect sizes (left column) Figure 1. Mean effect sizes and statistical significance for DNAm at birth and in childhood. Mean effect sizes (entertaint) and mean effective right collumn) are the total distribution analyses utilizing maximum available sample sizes. Lower row displays result from analyses with cohorts removed to achieve equal The autosomal DNAM sites per outcome point. The angle point of points and the sizes serom analyses with cohorts removed to achieve equal sample sizes at both time points Effect size is given as absolute regression coeffic from analyses with cohorts removed to achieve equal sample sizes at both time points.
Effect size is given as absolute regression coefficient ($|\overline{\beta}|$), representing the difference in
child health outcomes in SD between Effect size is given as absolute regression coefficient $(|\overline{\beta}|)$, representing the difference in child health outcomes in SD between full or no methylation in the case of continuous outcomes (ADHD, general psychopatholo outcomes (ADHD, general psychopathology, sleep duration and BMI), or log(odds ration)
18 outcomes (ADHD, general psychopathology, sleep duration and BMI), or log(odds ratio) for

categorical outcomes (asthma diagnosis). Statistical significance is given as mean absolute Z-

cape sence of lower p-values than expected assuming a null effect. Distributions are given for
DNAm effects at birth (left), in childhood (middle) and for change in effect between birth
and childhood (right) per outcome (c values
Figure 2
represe
presenc \overline{a} represents expected distribution of p-values by chance. Upwards deviations indicate higher
presence of lower p-values than expected assuming a null effect. Distributions are given for
DNAm effects at birth (left), in child and childhood (right) per outcome (color). Grey are displays the 95% confidence interval of and childhood (right) per outcome (color). Grey are displays the 95% confidence interval of
the null distribution.
Figure 3. Correlations between DNAm effects at birth and childhood and across outcom

the null distribution.
Figure 3. Correlations between DNAm effects at birth and childhood and across outcomes
This correlation matrix displays spearman correlations between regression coefficients for
DNAm at high and abil The numerous
Figure 3. Correlation
This correlation matr
DNAm at birth and ch
positive correlations |
|
|} Figure 3. Correlations between DNAm effects at birth and childhood and across outcomes. The correlation matrix displays spearman correlations contents for egenerate research in the DNAm at birth and blue lower negative correlations.
Figure S1. Distribution of effect sizes and statistical significance for DNAm

PON MORE CORRECTED AND MORE CORRECTED MORE ON A UPPER SUPPORTHOUS MORE POSITIVE CONTROLLED AND THE POSITIVE CO
Dispute S1. Distribution of effect sizes and statistical significance for DNAm at birth and childhood. Mean eff positive Correlation in the Supering Prigure S1. Distribution of effect sizes and statistical significal significal sides
Childhood. Mean effect sizes (left column) and mean statis
across all tested autosomal DNAm sites pe Figure S1. Distribution of effect sizes and statistical significance for DNAm at birth and in across all tested autosomal DNAm sites per outcome (y-axis) and time point. Upper row
displays results from analyses utilizing maximum available sample sizes. Lower row displays
results from analyses with cohorts removed displays results from analyses utilizing maximum available sample sizes. Lower row displ
results from analyses with cohorts removed to achieve equal sample sizes at both time
points. Effect size is given as absolute regre results from analyses with cohorts removed to achieve equal sample sizes at both time
points. Effect size is given as absolute regression coefficient ($|\overline{\beta}|$), representing the
difference in child health outcomes in SD points. Effect size is given as absolute regression coefficient ($| \beta |$), representing the difference in child health outcomes in SD between full or no methylation in the case continuous outcomes (ADHD, general psychopath difference in child health outcomes in SD between full or no methylation in the case of
continuous outcomes (ADHD, general psychopathology, sleep duration and BMI), or
log(odds ratio) for categorical outcomes (asthma diagn and the in child health outcomes (ADHD, general psychopathology, sleep duration and BMI), or
log(odds ratio) for categorical outcomes (asthma diagnosis). Effect sizes are displayed of
log-scale but y-axis units are in orig continuous outcomes (ADM) in particle graduate and an BMI), or
log(odds ratio) for categorical outcomes (asthma diagnosis). Effect sizes are displayer
log-scale but y-axis units are in original units. Statistical significa log-scale but y-axis units are in original units. Statistical significance is given as mean
absolute Z-values and again displayed on a log-scale.
Figure S2. Manhattan plot of DNAm associations at birth or in childhood. Man

absolute Z-values and again displayed on a log-scale.

Figure S2. Manhattan plot of DNAm associations at birth or in childhood. Manhatta

displaying the -log₁₀ p-value (y-axis) for DNAm associations at birth (bottom plot Figure S2. Manhattan plot of DNAm associations at laisplaying the -log₁₀ p-value (y-axis) for DNAm associations at laisplaying the -log₁₀ p-value (y-axis) for DNAm associations. Figure 52. Manhattan plot of DNAm associations at birth of in childhood. Manhattan plot displaying the -log₁₀ p-value (y-axis) for DNAm associations at birth (bottom plots) or in childhood (upper plots) per site (x-axis childhood (upper plots) per site (x-axis) per outcome. Red line indicates genome-wide
significance (Bonferroni: 1/number of tested probes), yellow line represents suggestive
threshold (1*10⁻⁵). Bottom ideogram displays c significance (Bonferroni: 1/number of tested probes), yellow line represents suggestive
threshold (1*10⁻⁵). Bottom ideogram displays cytobands.
Figure S3. Manhattan plot of association change. Manhattan plot displaying

threshold (1*10⁻⁵). Bottom ideogram displays cytobands.
Figure S3. Manhattan plot of association change. Manhattan plot displaying the -log₁₀ p-
value (y-axis) for change in DNAm association from birth to childhood p per outcome. Red line indicates genome-wide significance (Bonferroni: 1/number of tested |
|
|} Figure 33. Manhattan plot of association change. Manhattan plot displaying the -log10 p-
value (y-axis) for change in DNAm association from birth to childhood per DNAm site (x-ax
per outcome. Red line indicates genome-wid value (y-ana) for change in Entrance change in DNAm association from birth to childhood probes), yellow line represents suggestive threshold $(1*10^{-5})$. Bottom ideogram displays cytobands.
Cytobands. probes), yellow line represents suggestive threshold (1*10⁻⁵). Bottom ideogram displays
cytobands.
Figure S4. Effect size change ratio across different p-value thresholds. Number of DNAm

probes), yellow line represents suggestive threshold (1*10 °). Bottom ideogram displays
cytobands.
F<mark>igure S4. Effect size change ratio across different p-value thresholds.</mark> Number of DNAn
sites with increasing effect size *f*
Figure S4. E
sites with ir $\frac{1}{2}$ sites with increasing effect size divided by number of DNAm sites with decreasing effect size
19 sites with increasing effect size divided by number of DNAm sites with decreasing effect size $\mathbf s$

from birth to childhood (y-axis). Y-axis values higher than 1 indicate more DNAm sites with increasing effect size vs decreasing. DNAm is categorized as changing according to different p-value thresholds of change (-log₁ p-value thresholds of change (-log₁₀ p-values; x-axis). No thresholding based on statistical
significance of change is applied on the left, but becomes increasingly stringent towards the
right. p-value thresholds of change (-log₁₀ p-value), while price increasingly stringent towards the
right.
Figure S5: Correlations between DNAm effects at birth and childhood and across

Figure S5: Correlations between DNAm effects at birth and childhood and across

outcomes in ASLPAC. This correlation matrix displays spearman correlations between ک
Figure
regres
red re ー
「
c regression coefficients for DNAm at birth and childhood and across outcomes. Intensity of
red represents higher positive correlations and blue lower negative correlations. Estimates
are based on ALSPAC cohort only. red represents higher positive correlations and blue lower negative correlations. Estimates red represents higher positive correlations and blue lower negative correlations. Estimates are based on ALSPAC cohort only. are based on ALSPAC cohort only.

- References
1. Min, J. L. et al. Genomic and phenotypic insights from an atlas of genetic effects on DNA
- methylation. *Nat. Genet.* **53**, 1311–1321 (2021).
2. Czamara, D. *et al.* Integrated analysis of environmental and genetic influences on cord blood
DNA methylation in new-borns. *Nat. Commun.* **10**, 1–18 (2019). methylation. *Nat.* Genet. 33, 1311–1321 (2021).
Czamara, D. *et al.* Integrated analysis of environr
DNA methylation in new-borns. *Nat. Commun.* 1
Joubert, B. R. *et al.* DNA Methylation in Newborr
- 2. Czamara, D. et al. Integrated analysis of environmental and genetic influences on cord blood
DNA methylation in new-borns. *Nat. Commun.* **10**, 1–18 (2019).
3. Joubert, B. R. *et al.* DNA Methylation in Newborns and Mat DNA methylation in new-borns. Nat. Commun. 10, 1–18 (2019).
Joubert, B. R. *et al.* DNA Methylation in Newborns and Maternal
Genome-wide Consortium Meta-analysis. A*m. J. Hum. Genet.* 98
Czamara, D. *et al.* Effects of str
- 3. Joubert, B. K. et al. DNA Methylation in Newborns and Materika Smoking in Pregnancy:
Genome-wide Consortium Meta-analysis. Am. J. Hum. Genet. **98**, 680–696 (2016).
4. Czamara, D. et al. Effects of stressful life-events Genome-wide Consortium Meta-analysis. Am. J. Hum. Genet. 58, 680–696 (2016).
Czamara, D. *et al.* Effects of stressful life-events on DNA methylation in panic disor
depressive disorder. *Clin. Epigenetics* 14, 55 (2022).
R
- 4. Czamara, D. et al. Effects of stressful life-events on DNA methylation in panic disorder and major
depressive disorder. Clin. Epigenetics 14, 55 (2022).
5. Rider, C. F. & Carlsten, C. Air pollution and DNA methylation: depressive disorder. C*lin. Epigenetics* 14, 55 (2022).
Rider, C. F. & Carlsten, C. Air pollution and DNA met
Epigenetics 11, 131 (2019).
Sailani, M. R. *et al.* Lifelong physical activity is associ
- 5. Rider, C. F. & Carlsten, C. Air pollution and DNA methylation: effects of exposure in humans. Clin.

5. Sailani, M. R. *et al.* Lifelong physical activity is associated with promoter hypomethylation of

genes involved i Epigenetics 11, 131 (2019).
Sailani, M. R. *et al.* Lifelong
genes involved in metabolis
in aged human skeletal mus 6. Saham, M. R. et al. Lifelong physical activity is associated with promoter hypomethylation of
genes involved in metabolism, myogenesis, contractile properties and oxidative stress resista
in aged human skeletal muscle.
- in aged human skeletal muscle. *Sci. Rep.* 9, 3272 (2019).
Reese, S. E. *et al.* Epigenome-wide meta-analysis of DNA methylation and childhood asthma. *J.*
Allergy Clin. Immunol. **143**, 2062–2074 (2019). in aged human skeletal muscle. Sci. Re*p. 9, 3272* (2019).
Reese, S. E. *et al.* Epigenome-wide meta-analysis of DNA
Allergy Clin. Immunol. **143**, 2062–2074 (2019).
Neumann, A. *et al.* Association between DNA methylatio 7. Allergy Clin. Immunol. **143**, 2062–2074 (2019).
8. Neumann, A. *et al. Association between DNA methylation and ADHD symptoms from birth to*
- school age: a prospective meta-analysis. Transl. Psychiatry 10, 398 (2020).
9. Vehmeijer, F. O. L. *et al.* DNA methylation and body mass index from birth to adolescence:
- school age: a prospective meta-analysis. Transl. Psychiatry 10, 398 (2020).
9. Vehmeijer, F. O. L. *et al.* DNA methylation and body mass index from birth to adolescence:
meta-analyses of epigenome-wide association studies school age: a prospective meta-analysis. Transl. Psychiatry 10, 398 (2020).
Vehmeijer, F. O. L. *et al.* DNA methylation and body mass index from birth
meta-analyses of epigenome-wide association studies. *Genome Med.* 12,
- 9. Vehmeijer, F. O. L. et al. DNA methylation and body mass index from birth to adolescence.
meta-analyses of epigenome-wide association studies. *Genome Med.* 12, 105 (2020).
10. Mulder, R. H. *et al.* Epigenome-wide chan meta-analyses of epigenome-wide association studies. Genome Med. 12, 105 (2020).
Mulder, R. H. *et al.* Epigenome-wide change and variation in DNA methylation in child
trajectories from birth to late adolescence. Hum. Mol.
- 10. Mulder, R. H. et al. Epigenome-wide change and variation in DNA methylation in childhood.

11. Xu, C.-J. *et al.* The emerging landscape of dynamic DNA methylation in early childhood. *BMC*
 Genomics **18**, 25 (2017). trajectories from birth to late adolescence. Hum. Mol. Genet. 30, 119–134 (2021).
Xu, C.-J. *et al.* The emerging landscape of dynamic DNA methylation in early childh
Genomics 18, 25 (2017). 11. Xu, C.-J. et al. The emerging landscape of dynamic DNA methylation in early childhood. BMC
Genomics 18, 25 (2017). $Genomics$ 18, 25 (2017).
- 12. The EWAS Catalog: a database of epigenome-wide association studies. Wellcome Open Research

/ Open Access Publishing Platform https://wellcomeopenresearch.org/articles/7-41/v2 (2022)

doi:10.12688/wellcomeopenres.17598
- popen Access Publishing Platform https://wellcomeopenresearch.org/articles/7-41/v2 (2022)
doi:10.12688/wellcomeopenres.17598.2.
Safi-Stibler, S. & Gabory, A. Epigenetics and the Developmental Origins of Health and Disease: Safi-Stibler, S. & Gabory, A. Epigenetics an
Parental environment signalling to the epi
phenotype. *Semin. Cell Dev. Biol.* **97**, 172– Parental environment signalling to the epigenome, critical time windows and sculpting the adu
phenotype. *Semin. Cell Dev. Biol.* **97**, 172–180 (2020).
14. Olin, A. *et al.* Stereotypic Immune System Development in Newborn
- phenotype. *Semin. Cell Dev. Biol.* **97**, 172–180 (2020).
Olin, A. *et al.* Stereotypic Immune System Development in Newborn Children. *Cell* 174, 1277-
1292.e14 (2018). phenotype. Semm. Cen Bev. Biol. 97, 172–180 (2020).
Olin, A. *et al.* Stereotypic Immune System Developmer
1292.e14 (2018).
Gervin, K. *et al.* Systematic evaluation and validation c
- 14. Olin, A. et al. Stereotypic immune System Development in Newborn Children. Cell 174, 1277-
1292.e14 (2018).
15. Gervin, K. *et al.* Systematic evaluation and validation of reference and library selection metho
for deco Gervin, K. *et al.* Sy
for deconvolution
Felix, J. F. *et al*. Co
- 15. Gervin, K. et al. Systematic evaluation and validation of reference and library selection methods
for deconvolution of cord blood DNA methylation data. Clin. Epigenetics 11, 1–15 (2019).
16. Felix, J. F. et al. Cohort 16. Felix, J. F. *et al.* Cohort profile: Pregnancy and childhood epigenetics (PACE) consortium. *Int. J.*
Epidemiol. 47, 22–23u (2018).
- 16. Felix, J. F. et al. Cohort prome. Fregnancy and childhood epigenetics (PACE) consortium. *Int. J.*
Epidemiol. 47, 22–23u (2018).
17. Rijlaarsdam, J. et al. DNA methylation and general psychopathology in childhood: an
e 17. Rijlaarsdam, J. *et al.* DNA methylation and general psychopathology in childhood: an
epigenome-wide meta-analysis from the PACE consortium. *Mol. Psychiatry* 28, 1128–1136
(2023). 17. Rijlaarsdam, J. et al. DNA methylation and general psychopathology in childhood: an
epigenome-wide meta-analysis from the PACE consortium. *Mol. Psychiatry* 28, 1128-
(2023).
- epigenome-wide meta-analysis from the PACE consortium. Mol. Psychiatry 28, 1128–1136
(2023).
Sammallahti, S. *et al.* Longitudinal associations of DNA methylation and sleep in children: a
meta-analysis. *Clin. Epigenetics* meta-analysis. Clin. Epigenetics 14, 83 (2022).
- 18. Sammananti, S. et al. Longitudinal associations of DNA methylation and sleep in children: a
meta-analysis. Clin. Epigenetics 14, 83 (2022).
19. Cardenas, A., Fadadu, R. P. & Koppelman, G. H. Epigenome-wide association meta-analysis. C*lin. Epigenetics* 14, 83 (2022).
Cardenas, A., Fadadu, R. P. & Koppelman, G. H
disease and the environment. J. Allergy Clin. In
Mendelson, M. M. *et al.* Association of Body M
- 19. Cardenas, A., Fadadu, A., F. Etheppendan, 19. A., Epigenome-mac association stands of antisglish
disease and the environment. J. Allergy Clin. Immunol. 152, 582–590 (2023).
20. Mendelson, M. M. *et al.* Association of disease and the environment. *J. Allergy Clin. Immunol.* **152**, 582–590 (2023).
20. Mendelson, M. M. *et al.* Association of Body Mass Index with DNA Methylation and Gene
Expression in Blood Cells and Relations to Cardiome 20. Mendelson, M. M. et al. Association of Body Mass Index with DNA Methylation and Gene
Expression in Blood Cells and Relations to Cardiometabolic Disease: A Mendelian Random
Approach. *PLOS Med.* 14, e1002215 (2017).
21.
- Expression in Blood Cells and Relations to Cardiometabolic Expression in Approach. PLOS Med. 14, e1002215 (2017).
Sun, D. *et al.* Body Mass Index Drives Changes in DNA Methylation. *Circ. Res.* 125, 824–833
(2019). Approach. *PLOS Med.* 14, e1002215 (2017).
Sun, D. *et al.* Body Mass Index Drives Change
(2019).
Arathimos, R. *et al.* Epigenome-wide associa 2019).
22. Arathimos, R. et al. Epigenome-wide association study of asthma and wheeze in childhood and
- adolescence. Clin. Epigenetics 9, 112 (2017). 22. Arathmos, R. et al. Epigenome-wide association study of asthma and wheeze in childhood and
adolescence. *Clin. Epigenetics* 9, 112 (2017).
22 adolescence. Clin. Epigenetics 9, 112 (2017).
- 23. Walton, E. et al. Characterizing the human methylome across the life course: midnigs from eight
UK-based studies. 2021.09.18.460916 Preprint at https://doi.org/10.1101/2021.09.18.460916
24. Kilanowski, A. *et al.* DNA
- UK-based Studies. 2021).
Uklanowski, A. *et al.* DNA methylation and aeroallergen sensitization: The chicken or the egg?
Clin. Epigenetics **14**, 114 (2022). (2021).
Kilanowski, A. *et al.* DNA methyl
Clin. Epigenetics **14**, 114 (2022).
- 25. Kilanowski, A. *et al.* Methylation risk scores for childhood aeroallergen sensitization: Results
from the LISA birth cohort. *Allergy* 77, 2803–2817 (2022). Clin. Epigenetics 14, 114 (2022).
Kilanowski, A. *et al. Methylation*
from the LISA birth cohort. *Allerg*
Schans, J. van der, Çiçek, R., de V
- 25. Khanowski, A. et al. Methylation risk scores for childhood aeroallergen sensitization: Results
from the LISA birth cohort. Allergy 77, 2803–2817 (2022).
26. Schans, J. van der, Çiçek, R., de Vries, T. W., Hak, E. & Hoe from the EISA birth cohort. Allergy 77, 2803–2817 (2022).
Schans, J. van der, Çiçek, R., de Vries, T. W., Hak, E. & Hoel
diseases and attention-deficit/hyperactivity disorder: A sy
Neurosci. Biobehav. Rev. **74**, 139–148 (2 diseases and attention-deficit/hyperactivity disorder: A systematic review and meta-analyses.
Neurosci. Biobehav. Rev. **74**, 139–148 (2017).
27. Demontis, D. *et al.* Genome-wide analyses of ADHD identify 27 risk loci, ref
- discription-definition-definition-definition-definition-definition-definition-defined and attention-definition-
definition-definition-definition-definition-definition-definition-definition-definition-definition-definition-Neurosci. Biobenav. Rev. 74, 139–148 (2017).
Demontis, D. *et al.* Genome-wide analyses of *a*
architecture and implicate several cognitive d
Neumann, A. *et al.* A genome-wide association
- 28. Neumann, A. *et al.* A genome-wide association study of total child psychiatric problems scores.
PLOS ONE 17, e0273116 (2022). architecture and implicate several cognitive domains. Nat. Genet. 55, 158–208 (2025).
Neumann, A. *et al.* A genome-wide association study of total child psychiatric problems
PLOS ONE 17, e0273116 (2022).
Cortese, S. *et a*
- 28. Neumann, A. et al. A genome-wide association study of total child psychiatric problems scores.

29. Cortese, S. *et al.* Association between attention deficit hyperactivity disorder and asthma: a

29. Cortese, S. *et a* PLOS ONE 17, e0273116 (2022).
Cortese, S. *et al.* Association beth
systematic review and meta-ana
717–726 (2018). 29. Cortese, S. et al. Association between attention deficit hyperactivity disorder and asthma: a
systematic review and meta-analysis and a Swedish population-based study. *Lancet Psychiat*
717–726 (2018).
30. Zhu, Y., Wan
- systematic review and meta-analysis and a Swedish population-based study. *Lancet Psychiatry 5,*
717–726 (2018).
Zhu, Y., Wang, N.-N., Pan, D. & Wang, S. Risk of Overweight and Obesity in Children and
Adolescents with Atte 7
2hu, Y., Wang, N.
Adolescents with
Analysis. *Child. O* 30. Zhu, Y., Wang, N.-N., Pan, D. & Wang, S. Risk of Overweight and Obesity in Children and
Adolescents with Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-
Analysis. *Child. Obes.* (2023) doi:10.10
- A are discovered with Attentional Neuroscence of Attention-Deficit Hyperactivity Disorder: A Analysis. Child. Obes. (2023) doi:10.1083/chi.2022.0230.
Lanoye, A., Adams, E. & Fuemmeler, B. F. Obesity and Att
in New Discoveries in the Behavioral Neuroscience of Atte
(eds. Stanford, S. C. & Sciberras, E.) 221–241 (Sp 31. Land, 3, C., 8. Science of Attention-Deficit Hyperactivity Disorder
(eds. Stanford, S. C. & Sciberras, E.) 221–241 (Springer International Publishing, Cham, 2022).
doi:10.1007/7854_2022_337. in New Discoveries in the Behavioral Neuroscience of Attention-Deficit Hyperactivity Disorder
(eds. Stanford, S. C. & Sciberras, E.) 221–241 (Springer International Publishing, Cham, 2022).
doi:10.1007/7854_2022_337.
Do, E
- (eds. Stanford, S. C. B. C. B. C. (Springer International Publishing, Cham, 2022).

Do, E. K. *et al.* The role of genetic and environmental influences on the association between

childhood ADHD symptoms and BMI. *Int. J.* \overline{a} Do, E. K. *et al.* The role of genes
childhood ADHD symptoms an 32. Bo, E. K. et al. The role of genetic and environmental influences on the association between
childhood ADHD symptoms and BMI. *Int. J. Obes.* 43, 33–42 (2019).
23 childhood ADHD symptoms and BMI. *Int. J. Obes.* 43, 33–42 (2019).

-
- 33. Bergstedt, J. et al. The immune factors driving DNA methylation variation in human blood. Nat.

Commun. 13, 5895 (2022).

34. Viechtbauer, W. Conducting Meta-Analyses in R with the metafor Package. J. Stat. Softw. 36, Commun. 13, 5895 (2022).
Viechtbauer, W. Conductin
48 (2010).
R Core Team. *R: A Languag*
- 48 (2010).
35. R Core Team. *R: A Language and Environment for Statistical Computing*. (R Foundation for
Statistical Computing, Vienna, Austria, 2022). 48 (2011).
R Core Tea
Statistical (
Phipson, B
- 35. R Core Team. R: A Language and Environment for Statistical Computing. (R Foundation for
Statistical Computing, Vienna, Austria, 2022).
36. Phipson, B., Maksimovic, J. & Oshlack, A. missMethyl: an R package for analyzin کر بنیادی کردی کردی Phipson, B., Maksimovic, J. & Oshlack, A. miss
Illumina's HumanMethylation450 platform. *Bi*
Maksimovic, J., Oshlack, A. & Phipson, B. Gene
- 37. Maksimovic, J., Oshlack, A. & Phipson, B. Gene set enrichment analysis for genome-wide DN
37. Maksimovic, J., Oshlack, A. & Phipson, B. Gene set enrichment analysis for genome-wide DN
37. Maksimovic, J., Oshlack, A. & Indiffice 3 HumanWethylation450 platform. Biomformates 32, 286–288 (2015).
Maksimovic, J., Oshlack, A. & Phipson, B. Gene set enrichment analysis for geno
methylation data. *Genome Biol.* 22, 173 (2021). methylation data. *Genome Biol*. 22, 173 (2021). methylation data. Genome Biol. 22, 173 (2021).

Table 1 Published epigenome-wide association studies of child developmental outcomes from PACE, jointly re-analyzed in present study

* Covariate only used in school-age analyses

Covariates considered in creation of BMI standard deviation scores

ADHD Attention Deficit Hyperactivity Disorder **GPF** General Psychopathology Factor **BMI** Body Mass Index **Age** Age at outcome **LMM** Linear Mixed Model**LM** Linear Model (OLS) **RLM** Robust Linear Model **Logistic** Logistic regression model **mat.** Maternal**edu.** Education **prop.** proportion **HE-RE** Han & Eskin Random Effects Model **FE** Fixed Effects Model **n_{cpg}** Number of CpG sites genome-wide significant **ⁿ** Sample size

	DNAm at Birth (Prospective EWAS)							DNAm in Childhood (Cross-sectional EWAS)						Change between time points				
Outcome	n_{cpg}		n n_{cohorts}	mean β (abs.)	mean SE	mean z	n_{cpg} p<0.05 (FDR/bonf.)		n n_{cohorts}	mean β (abs.)	mean SE	mean z	n_{cpg} p<0.05 (FDR/bonf.)	n_{cohorts} both	Δβ	N_{cpg} +Δβ	N_{cpg} -Δβ	Δz
ADHD	430327	2477	6	1.03	1.10	1.02	57339 (896/3)	2374	5	1.39	1.76	0.78	19034 (0/0)		3 0.36	10542(0/0)	6841(0/0)	-0.23
GPF	372292	2178	4	.23	1.59	0.78	16549 (0/0)	2190	5	1.50	1.98	0.78	17767 (1/1)		30.27	13375(1/1)	6475(0/0)	0.01
Sleep	431159	3658	10	0.97	1.30	0.76	17399 (0/0)	2539	5	1.59	2.06	0.77	18113 (0/0)		4 0.63	14447 (0/0)	5171(0/0)	0.01
BMI	435652	4102	14	0.77	1.04	0.75	16012 (0/0)	3406	11	1.10	.29	0.86	30615 (2/1)		6 0.33	23793(0/0)	6634(0/0)	0.11
Asthma	432728	3065 (631)	$\overline{7}$	2.70	3.44	0.82	26112 (0/0)	2834 (631)	9	2.94	3.92	0.77	18605 (66/11)		$0\quad 0.24$	18024(2/2)	9678(2/0)	-0.06

Table 2 Association between DNA methylation either at birth or in childhood and child developmental outcomes (full sample)

ADHD Attention Deficit Hyperactivity Disorder

GPF General Psychopathology Factor

BMI Body Mass Index

ncpg Number of CpG sites tested

ⁿ Sample size (cases)

n_{cohorts} Number of cohorts

mean β **(abs.)** The mean absolute regression coefficient across DNAm sites. β represents the expected difference in the outcome in SD when CpG sites is fully methylated compared to no methylation. For asthma, β represents the log(odds) difference

Mean SE Mean Standard Error

Mean z Mean z values across CpG sites. z=β/SE indicating statistical significance

n_{cpg} p<0.05 (FDR/bonf.) Number of nominally significant CpG sites (after adjustment for false discovery rate/after Bonferroni adjustment)

n_{cohorts} both Number of cohorts which contributed to both birth and school age analyses

Δβ Change in effect size from birth to school age

Ncpg+Δβ Number of CpG sites with increasing effect size and nominally significant change (FDR/Bonferroni)

Ncpg--Δβ Number of CpG sites with decreasing effect size and nominally significant change (FDR/Bonferroni)

Table 3 Comparison of birth EWAS (i.e. prospective analysis) versus childhood EWAS (i.e. cross-sectional analysis): Overview of study findings

Table 4 Gene ontology enrichment analyses: top 10 terms for phenotype-associated DNAm sites showing change from birth to childhood

medRxiv preprint doi: https://doi.org/10.1101/2024.02.29.24303506; this version posted February 29, 2024. The copyright holder for this preprint
(which was not certified by peer review) is the author/tunder, who has grante The copyright holder for this preprint holder for this version posted February 29, 2024. The copyright holder for this preprint the copyright holder for this preprint. who has granted by perfact in the author/funder, who has granted medRxix a license to display the preprint in perpetuity. . [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) It is made available under a

Full sample size Effect size

Full sample size Statistical significance

DNAm at Birth

DNAm at Childhood

Change from Birth to Childhood

β correlations between time points and outcomes